



Government of Pakistan
Ministry of National Health Services, Regulations & Coordination
Drug Regulatory Authority Of Pakistan
Health & OTC Products Division (Non-Drugs)

Islamabad, the 04th January, 2022

“SAY NO TO CORRUPTION”


SUBJECT: SUBMISSION OF DEFICIENT INFORMATION / DOCUMENTS

The applications of following applicants were placed before the Enlistment Evaluation Committee (EEC) in its 111th meeting held on 30th August, 2022 and the same have been deferred being deficient of the information / documents as specified in column (3) of the Table below which may be furnished within 20 days of uploading of this letter on official website of DRAP along with soft data as per **Annexed Format** at the end of this letter/document. Replies received after given time will not be entertained:-


S.No	Brand name	Decision
(1)	(2)	(3)
For Export Purpose Only		
M/s Nutrevo Healthcare, Khewat No. 438, Khatauni No.452, Khasra No. 819, 14 – Km Adyala Road, Rawalpindi		
1.	Lactolac Milk Powder	Deferred for clarification of formulation as per 100g provisions of COAs, Undertakings and change of brand name
For Export Purpose Only		
M/s Human Health Pharma, Plot No. 76, A5, Sector 12C, North Karachi Industrial Area, Karachi,		
2.	Ormig Pro Sachet	Deferred since the formulation registered as drug
M/s Marhaba Laboratories (Pvt.) Ltd., 142 Main Quaid-e-Azam Industrial Estate Lahore (E. No. 00730)		
3.	MARHABA JAWARISH SHAHI AMBRI	Deferred for clarification and provision of Pearls monograph also provide Form-E of the consignment sent to UAE in 2022 (6867\$)
4.	MARHABA URINOL CAPSULE	Deferred for clarification of Potassium carbonate and provision of signed Form-3
5.	MARHABA URIFLOW CAPSULE	Deferred for clarification of Potassium carbonate in unani formulation
6.	MARHABA SURANJEENA CAPSULE	Deferred for clarification of Styrax benzoin in unani formulation
7.	MARHABA TYPHIL SYRUP	Deferred for clarification of Zinc in unani formulation
8.	MARHABA JOSHANDA (compound Zinc)	Deferred for clarification of zinc compound in unani formulation
9.	MARHABA FLUNIL DROPS	Deferred for clarification of zinc compound in unani formulation
10.	MARHABA GOSHOON OIL	Deferred for clarification of copper sulphate in unani formulation
M/s SOIS Life Sciences (Pvt) Ltd Plot No. G-77, S.I.T.E, Super Highway, Phase – II, Karachi (E. No. 01304)		
11.	NOBLOCK DROP	Deferred for clarification regarding applied formulation and dosage form and justification of formulation as health product
12.	SELVEX Liquid	Deferred for clarification regarding applied formulation and dosage form
13.	CUFBEES Nasal drops	Deferred for clarification regarding applied formulation and dosage form and justification of formulation as health product
14.	VIVO NASAL Drops	Deferred for clarification regarding applied formulation and dosage form and justification of formulation as health product
M/s GlaxoSmithKline Consumer Healthcare Pakistan Limited, 35-Dockyard Road, West Wharf Road, Karachi agent of M/s Pfizer Consumer Manufacturing, Italy, S.r.L, Via Nettunense 90, 04011, Aprillia, Italy (E. No. 01312)		
15.	Centrum Adult Tablet	Deferred for following reasons: • Confirmation of registration status of Centrum brand from PE&R Division.
M/s. Galaxy Pharma (Private) Limited, located at D-180, Rojhan Street, Block-5, Clifton, Karachi-75600, Pakistan is Agent of M/s. Lo. Li Pharma International, Roma – 00156 – VIA dei LUXARDO, 33 – VAT. 067851002, Italy (E. No. 00056)		
16.	Delphys Tablet	Deferred for following reasons: • Long term and accelerated Stability Studies data not provided.
M/s QAS International, located at the address Opposite King Mall, Near WAPDA Town, G.T Road, Gujranwala is an agent of M/s SUPER'S DIANA, S.L., CTRA. C-17, KM 17, 08150 Parets del Valles – Spain (E. No. 00866)		
17.	Impak Oral Solution (Vet)	Deferred for following reasons:

S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provided by the firm.
M/s AddLeven Pharma (SMC-Pvt.) Ltd., Suite No.6, First Floor, Paramount Plaza, G-15 Markaz, Islamabad, as an agent of M/s ValueMed Pharma S.r.l located at Via 28 Luglio, 211, 47893 Borgo Maggiore, Rep. San Marino, Italy (Principal Manufacturer: M/s Erbex S.r.l located at Via Del Laghetto, n110, Badia Polesine (Rovigo), Italy (E. No. 00982)		
18.	Natural Paus Forte Cap	Deferred for following reasons: <ul style="list-style-type: none"> Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provided by the firm.
19.	Best Berry Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provided by the firm.
20.	Esil Natur	Deferred for following reasons: <ul style="list-style-type: none"> Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provided by the firm.
21.	Calcitrix Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provided by the firm.
22.	Memory Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provided by the firm.
23.	Prostaparen Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provided by the firm.
24.	EveryDay Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provided by the firm.
25.	Lipid Low Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provided by the firm.
26.	Aid To Vision	Deferred for following reasons: <ul style="list-style-type: none"> Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provided by the firm.
27.	Glutamax Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provided by the firm.
28.	NutriJoint Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provided by the firm.
29.	Actinatur Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provided by the firm.
30.	Cystoff Table	Deferred for following reasons: <ul style="list-style-type: none"> Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provided by the firm.
31.	Roalac Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provided by the firm.
32.	Extravenus Capsule	Deferred for following reasons: <ul style="list-style-type: none"> Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provided by the firm.
33.	Ferselle Sachet	Deferred for following reasons:

S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provided by the firm.
34.	Fersen Sachet	Deferred for following reasons: <ul style="list-style-type: none"> Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provided by the firm.
35.	Entero Junior Oral AMP	Deferred for following reasons: <ul style="list-style-type: none"> Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provided by the firm.
36.	Probiotics & Vitamins Oral AMP	Deferred for following reasons: <ul style="list-style-type: none"> Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provided by the firm.
37.	Emorlex Cream	Deferred for following reasons: <ul style="list-style-type: none"> Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provided by the firm.
38.	Centella Gel	Deferred for following reasons: <ul style="list-style-type: none"> Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provided by the firm.
39.	Horse ChestNut Gel	Deferred for following reasons: <ul style="list-style-type: none"> Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provided by the firm.
40.	Extravenus Gel	Deferred for following reasons: <ul style="list-style-type: none"> Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provided by the firm.
41.	Gynepink Remedy Pessaries	Deferred for following reasons: <ul style="list-style-type: none"> Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provided by the firm.
M/s BHP Homoeo Laboratories (Pvt) Ltd., Paragon Industrial Estate, 18-Km, Multan Road, Lahore (E. No.00624)		
42.	BHP's INSOMAX DROPS	Deferred for safety profile of product is required
43.	BHP's Gyno Pro Syrup	Deferred for change of brand name
44.	BHP's Baby Rebiotic Syrup	Deferred for change of brand name
45.	BHP's FEVO..LESS Syrup	Deferred for change of brand name and Rhus tox is toxic in 3x potency raise the potency to 6x or above
46.	BHP's Kuf Lik-P Syrup	Deferred for change of brand name
47.	BHP's KUF LIK-SF SYRUP	Deferred for change of brand name
M/s. Blossom Laboratories (Pvt.) Ltd., 30-KM, Badian Road, ½ K.M Off Roda Bohgal Road, Lahore Cant. (E. No.00181)		
48.	Blossom's Colic Syrup	Deferred for change of brand name
49.	Hepalex Syrup	Deferred for change of brand name
50.	Nervo Plus Syrup	Deferred for change of brand name
51.	Sepia officinalis (EHPI)	Deferred for sarcode testing of sepia is required
52.	Condurango (EHPI)	Deferred for Homeopathic monograph of Condurango is required
53.	Cantharis (EHPI)	Deferred for sarcode testing of Cantharis is required
54.	Calcarea renalis (EHPI)	Deferred for Homeopathic monograph of renalis calcarean is required
55.	Cantharis (EHPI)	Deferred for sarcode testing of cantharis is required
56.	Cholesterinum (EHPI)	Deferred for Homeopathic monograph of Cholesterine is required
57.	Lac defloratum (EHPI)	Deferred for sarcode testing of Lac defloratum is required
58.	Formica rufa (EHPI)	Deferred for sarcode testing of Formica rufa is required
59.	Sepia officinalis (EHPI)	Deferred for sarcode testing of sepia is required
60.	Serum anguillae (EHPI)	Deferred for sarcode testing of Eel serum is required
61.	Coccus Cacti Potency (EHPI)	Deferred for sarcode testing of Coccus Cacti is required
62.	Coughsolax Syrup	Deferred for change of brand name
63.	Hemolex Syrup	Deferred for change of brand name
64.	Hepagold Syrup	Deferred for change of brand name
65.	Ulcelex Syrup	Deferred for change of brand name
66.	Super Fresh Blood Syrup	Deferred for change of brand name
67.	Hepa Max Syrup	Deferred for change of brand name



S.No	Brand name	Decision
(1)	(2)	(3)
68.	Gasto..P Syrup	Deferred for change of brand name
69.	Be..Fit Powder	Deferred for change of brand name
70.	Self Guard Tablet	Deferred for change of brand name
71.	Alfalpa+Ginseng Syrup	Deferred for change of brand name
72.	B..Cool Tablet	Deferred for change of brand name
73.	B..Vision Tablet	Deferred for change of brand name
74.	Histalex Syrup	Deferred for change of brand name
75.	Uro Stop Syrup	Deferred for change of brand name
76.	Blood Off Tablet	Deferred for change of brand name
77.	Face Care Tablet	Deferred for change of brand name
78.	Matti Chor Tablet	Deferred for change of brand name
79.	Smoke Stop Tablet	Deferred for change of brand name
80.	Weight Plus Tablet	Deferred for change of brand name
81.	Pilzee Tablet	Deferred for change of brand name
82.	Piles One Capsule	Deferred for change of brand name
83.	Cigarette ChhorTablet	Deferred for change of brand name
84.	Neurozion Syrup	Deferred for change of brand name
85.	Ashoka Cordial Syrup	Deferred for change of brand name
86.	Bed Wetting Syrup	Deferred for change of brand name
87.	Coughlex Syrup	Deferred for change of brand name
88.	Feverlex Syrup	Deferred for change of brand name
89.	Gynolex Syrup	Deferred for change of brand name
90.	Luzogen Syrup	Deferred for change of brand name
91.	Mega Mass Syrup	Deferred for change of brand name
92.	Thandak Syrup	Deferred for change of brand name
93.	Ginkolex Tablet	Deferred for change of brand name
94.	Leco Care Tablet	Deferred for change of brand name
95.	Piles Shoot Syrup	Deferred for change of brand name
M/s D.M.A Homeo Lab, 19..Km, Ferozepure Road, Lahore (E. No.01009)		
96.	DMA'S HEIGHT COMPOUND DROPS	Deferred for sarcod testing(TSE,BSE,Ecoli)is required or evidence that source is free from TSE,BSE and Ecoli
M/s. Dr. Zia Homeopathic Pharma DZHP, Plot No. 18, Sector - 14 Korangi Industrial Area, Karachi (E. No.00176)		
97.	Histaminum (Potencies)	Deferred for Homeopathic monograph of Histamine is required
98.	Hydrophobinum (Potencies)	Deferred for Homeopathic monograph of Lyssin is required
99.	Insulinum (Potencies)	Deferred for sarcod testing of source is required
100.	Pituitary gland (Potencies)	Deferred for sarcod testing of source is required
101.	Adrenalinum (Potencies)	Deferred for sarcod testing of source material is required
102.	Sepia Officinalis Ø (Mother tincture)	Deferred for sarcod testing of source material is required
103.	Bufo Rana Ø (Mother tincture)	Deferred for sarcod testing of source material is required
M/s. Islamabad Pharmacy, Behind Qadir Gas Way 1, G.T. Road Wah District, Rawalpindi (E. No.00270)		
104.	Islamabad Pharmacy's Phosphorus potencies	Deferred for Homeopathic monograph of Phosphorus is required
105.	Islamabad Pharmacy's Plumbum met potencies	Deferred for Homeopathic monograph of Plumbum met is required
106.	Islamabad Pharmacy's Robinapseu potencies	Deferred for sarcod testing of Yellow locust is required
107.	Islamabad Pharmacy's Sepia potencies	Deferred for sarcod testing of Inky juice of cuttlefish is required
108.	Islamabad Pharmacy's Sulphur potencies	Deferred for Homeopathic monograph of Sulphur is required



S.No	Brand name	Decision
(1)	(2)	(3)
109.	GR Pilogen Ointment	Deferred for change of brand name
110.	GR Crack Care Cream	Deferred for change of brand name
111.	GR Burn aid Ointment	Deferred for change of brand name
112.	GR Sunscreen Cream	deferred for monograph of Chamomile is required
113.	GR B-glow Cream	Deferred for change of brand name
114.	GR Acne care Cream	Deferred for change of brand name
115.	GR Dura max Cream	Deferred for change of brand name
116.	GR Warts Cure Ointment	Deferred for change of brand name
117.	GR SELFARE Tablets	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
118.	GR HIOGEN Tablets	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
119.	GR Calcimax Syrup	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
120.	GR Flu GoSyrup	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
121.	GR IvyKuff Syrup	Deferred for change of brand name
122.	GR Ginseng Syrup	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
123.	GR Moringaoleifera Syrup	Deferred for evidence of fee submission is required
124.	GR Gum paint Drops	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
125.	GR Roghan e khashkhash	Deferred for change of brand name
126.	GR Krela Capsule	Deferred for change of brand name
127.	GR Lesona Capsule	Deferred for change of brand name
128.	GR MensoreenCapsule	Deferred for change of brand name
129.	Croup off Tablet	Deferred for change of brand name
130.	Islamabad pharmacy's Antim crud potencies	Deferred for safety profile of product is required
131.	Islamabad pharmacy's Cholesterinum potencies	Deferred for source of cholestterine is required
132.	World Arq e HepaNil	deferred for change of brand name
133.	World Arq e KabirKhas	Deferred for change of brand name
134.	World Arq e Supari Pak	deferred for change of brand name
M/s. Kamal Laboratories Sukho, District Rawalpindi (E. No.0020)		
135.	KL-71 DROPS	Deferred for clarification regarding facility ,source ,production, and storage of x ray formation is required Homeopathic monograph of X rays is required The applied formulation contains radioactive substance X rays
136.	KL-77 DROPS	Deferred for clarification regarding the formulation
137.	KL-78 DROPS	Deferred for clarification regarding facility ,source ,production, and storage of Radium formation is required Homeopathic monograph of X rays is required The applied formulation contains radioactive substance radium
138.	Acetone	Deferred for Homeopathic monograph of Acetone is required
139.	Achromycin	Deferred for Homeopathic monograph of Tetracycline hydrochloride is required
140.	X Ray	Deferred for The applied formulation contains Radioactive substance X rays
141.	Albucid	Deferred for Homeopathic monograph of Albucid is required

S.No	Brand name	Decision
(1)	(2)	(3)
142.	Alloxin	Deferred for The applied formulation contains toxic glucose analogue, which selectively destroys insulin-producing cells in the pancreas (that is, beta cells) when administered Homeopathic monograph of Alloxin
143.	Aminophyllin	Deferred for Justification regarding stability of aminophylline in oral solution form is required Homeopathic monograph of Aminophyllin is required
144.	Araldite	Deferred for Homeopathic monograph of Araldite (synthetic adhesive) is highly toxic when taken orally, Justification is required for its use as orally
145.	Asbestos	Deferred for Homeopathic monograph of Asbestos is required Asbestos is highly poisonous and cause Lung cancer, Justification is required for its use as orally Asbestos is banned item By EPA,(NIOSH) due to its air born particle hazards
146.	Aureomycin	Deferred for Homeopathic monograph of Aureomycin is required
147.	Benadryl	Deferred for The firm applied product with brand name/market name Benadryl contains Diphenhydramine and Homeopathic monograph is required
148.	Busubhan	Deferred for Homeopathic monograph of Busubhan is required
149.	Butazolidin	Deferred for Homeopathic monograph of Butazolidin is required
150.	Chloramine-T	Deferred for Homeopathic monograph of Chloramine-T is required
151.	Chloramphenical	Deferred for Homeopathic monograph of Chloramphenical is required
152.	Chloroform	Deferred for The applied formulation contains chloroform which is highly toxic when taken orally as due to its respiratory and cardiac arrest
153.	Chlorothiazide	Deferred for Homeopathic monograph of Chlorothiazide is required
154.	Chlorpromazine Hydrochloride	Deferred for Homeopathic monograph of Chlorpromazine-Hydrochloride is required furthermore its antipsychotic drug
155.	Chlortetracycline Hydrochloride	Deferred for Homeopathic monograph of Chlortetracycline Hydrochlorid is required
156.	Cobal Rays	Deferred for Homeopathic monograph of Cobalt rays is required The facility for source ,formation, handling ,production of cobalt rays is required
157.	Cortine	Deferred for Homeopathic monograph of Deoxycortone acetate is required The applied formulation contains steroidal preparation of Deoxycortone acetate as sterile facility is required
158.	Cresol	Deferred for Homeopathic monograph of Cresol is required
159.	Dapsone	Deferred for Homeopathic monograph of Dapsone is required
160.	Dichloro Diphenyl Trichloroethane	Deferred for The applied formulation contains Insecticides DDT(Dichloro Diphenyl Trichloroethane) which is highly poisonous when taken orally
161.	Durabolin	Deferred for The applied formulation contains anabolic steroids (Nandrolone cyclohexylpropionate
162.	Electricity	Deferred for Justify the role of electricity in homeopathic use along with Homeopathic monograph
163.	Emetin Hydrochloride	Deferred for Homeopathic monograph of Emetin Hydrochloride is required
164.	Endoxan	Deferred for The applied formulation contains Cyclophosphamide which is immunosuppressant drug

S.No	Brand name	Decision
(1)	(2)	(3)
165.	Ergotina	Deferred for Homeopathic monograph of Ergotina is required
166.	Erythromycin	Deferred for Homeopathic monograph of Erythromycin is required
167.	Ether	Deferred for Homeopathic monograph of Ether is required Furthermore diethyl ether is highly flammable
168.	Flagyl	Deferred for The firm applied product with brand name Flagyl Homeopathic monograph of Metronidazol is required
169.	Formalin	Deferred for The applied formulation contains Formalin which is highly poisonous when taken orally
170.	Gamma	Deferred for The applied formulation contains Gamma rays which is radioactive substance
171.	Chlortetracycline Hydrochloride	Deferred for Homeopathic monograph of Chlortetracycline Hydrochloride is required
172.	KL-64 DROPS	Deferred for justification and clarification of formulation
173.	Amygdale	Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
174.	Aorte	Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
175.	Artere Carotide	Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
176.	Artere	Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
177.	Ovarinum	Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
178.	Bulbinum	Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
179.	Cardine	Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
180.	Cartilago	Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
181.	Cerebellum	Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
182.	Cerebrinum	Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
183.	Coccyx	Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
184.	Colon (Muqueuse du)	Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
185.	Corps Jaune	Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
186.	Cortex Surrenal	Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
187.	Disci Cervicales	Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
188.	Disci Lumbales	Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
189.	Epiphyse	Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
190.	Estomac	Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
191.	Ganglions Lymphatiques	Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
192.	Gencives	Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
193.	Glandes Mammaires	Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
194.	Glandes Surrenales	Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
195.	Parotidinum	Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli

S.No	Brand name	Decision
(1)	(2)	(3)
196.	Hypophysine LA	Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
197.	Pancreine	Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
198.	Hypophysine	Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
199.	Pancreine	Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
200.	Intestine Gros	Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
201.	Langue	Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
202.	Larynx	Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
203.	Ligaments	Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
204.	Mamelline	Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
205.	Medulline	Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
206.	Meduloss	Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
207.	Muqueuse Endo	Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
208.	Muqueuse Gastrique	Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
209.	Orchitinum	Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
210.	Muqueuse Intestinale	Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
211.	Muqueuse Laryngee	Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
212.	Muqueuse Linguale	Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
213.	Muqueuse Sinusale	Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
214.	Muqueuse Stomacale	Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
215.	Muqueuse Uterine	Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
216.	Muscle Lisse	Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
217.	Muscle Oculaires	Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
218.	Nerfs Moteur	Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
219.	Nerfs Occipital	Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
220.	Nerfs Optique	Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
221.	Nerfs Parasympathique	Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
222.	Nerfs	Deferred for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
223.	FERRIN CAPSULES	Deferred for Homeopathic monograph of Folic acid, Vitamin B12 are required Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
M/s Mansoor Homoeo Pharma, LS-35, St-10/A, Block No.16, F.B. Area, Karachi (E. No.00419)		
224.	C5 GASTRONIN Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
225.	C7 NEURALGION Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
226.	C8 SINUTON Drops	Deferred for



S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
227.	C9 RHEUMATON Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
228.	NEFRO COMPLEX Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
229.	CARDUUS COMPLEX Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
230.	HAIR COMPLEX Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). • The applied formulation contains Juglans Regis in 3x prepartion which is toxic and revise the potency with 6x or above.
231.	MHP ... 1 GERD Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
232.	MHP ... 2 RUMACARB Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). • The applied formulation contains Bryonia alba and Rhus tox in 3x prepartion which is toxic and revise the potency with 6x or above.
233.	MHP ... 3 DETRULITH Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). • The applied formulation contains Berberis vulgaris in Q preparation which is toxic and revise the potency with 6x or above.
234.	MHP ... 4 HEMORECT Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
235.	MHP ... 5 DERMECH Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name

S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). The applied formulation contains Rhus tox in 3x prepartion which is toxic and revise the potency with 6x or above.
236.	MHP ... 6 HEPAMAG Drops	Deferred for <ul style="list-style-type: none"> Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
237.	MHP ... 7 LEUCOHYDE Drops	Deferred for <ul style="list-style-type: none"> Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
238.	MHP ... 8 ANXINAP Drops	Deferred for <ul style="list-style-type: none"> Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). The applied formulation contains Aconite in 3x prepartion which is toxic and revise the potency with 6x or above.
239.	MHP ... 9 VOMEZ Drops	Deferred for <ul style="list-style-type: none"> Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
240.	MHP ... 10 WORMGARD Drops	Deferred for <ul style="list-style-type: none"> Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
241.	MHP ... 11 SINUX Drops	Deferred for <ul style="list-style-type: none"> Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). The applied formulation contains Bryonia and aconite in 3 x prepartion which is toxic and revise the potency with 6x or above.
242.	MHP ... 12 DYROSOL Drops	Deferred for <ul style="list-style-type: none"> Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
243.	MHP ... 13 DIALOX Drops	Deferred for <ul style="list-style-type: none"> Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
244.	MHP ... 14 CALADEX Drops	Deferred for <ul style="list-style-type: none"> Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
245.	MHP ... 15 PYROX Drops	Deferred for

S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). • The applied formuation contains Aconite,Belladonanand rhus tox in 3x preapartion which is toxic and revise the potency with 6x or above.
246.	MHP ... 16 URIX Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
247.	MHP ... 17 ACNE FACE TONE Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
248.	MHP ... 18 CERVINEX Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
249.	MHP ... 19 PROSTOMALE Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
250.	MHP ... 20 DENGNAL Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
251.	MHP ... 21 ASTHAM Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
252.	MHP ... 22 GOLD DROPS Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
253.	MHP ... 23 MENSTRAL Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
254.	MHP ... 24 BRAIN TONIC Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
255.	MHP ... 25 SMART Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name

S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
256.	MHP ... 27 VITILEC Drops	Deferred for <ul style="list-style-type: none"> Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
257.	MHP ... 28 INFISORE Drops	Deferred for <ul style="list-style-type: none"> Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
258.	MHP ... 29 LAXORECT Drops	Deferred for <ul style="list-style-type: none"> Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
259.	MHP ... 30 GINGI Drops	Deferred for <ul style="list-style-type: none"> Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
260.	MHP ... 31 MIGRA Drops	Deferred for <ul style="list-style-type: none"> Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
261.	MHP ... 32 ENURIT Drops	Deferred for <ul style="list-style-type: none"> Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
262.	MHP ... 33 HBP Drops	Deferred for <ul style="list-style-type: none"> Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
263.	MHP ... 34 ANOREXIA Drops	Deferred for <ul style="list-style-type: none"> Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
264.	MHP ... 35 HL...TALL Drops	Deferred for <ul style="list-style-type: none"> Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
265.	MHP ... 36 EAR...EZ Drops	Deferred for <ul style="list-style-type: none"> Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
266.	MHP ... 37 EYEZOL Drops	Deferred for <ul style="list-style-type: none"> Confirmation/Availability of Homeopathic Drops Section.

S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
267.	MHP ... 38 NERVOL Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
268.	MHP ... 39 HOL...FIX Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
269.	MHP ... 40 HAIR CARE Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
270.	MHP ... 41 TRAUMIX Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
271.	MHP ... 42 MOUTH SORE Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
272.	MHP...43 STIMULATION TONIC Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
273.	MHP ... 44 ALBUTOX Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
274.	MHP ... 45 GINSENG BOOST Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
275.	MHP ... 46 GALTOX Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
276.	MHP ... 47 EPILEPSOL Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
277.	MHP ... 48 FALIJEX Drops	Deferred for

S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
278.	MHP ... 49 TONSINIL Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
279.	MHP ... 50 THYROXINIL Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
280.	MHP ... 51 VERTILEX Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
281.	MHP ... 52 MORBINIL Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
282.	MHP ... 53 TUMEDIC Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
283.	MHP ... 54 HERNIZIP Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
284.	MHP ... 55 SCIATILAX Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
285.	MHP ... 56 SHAPEUP Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
286.	MHP ... 57 PAPILLOMA Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
287.	MHP ... 58 NICOTOX Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).

S.No	Brand name	Decision
(1)	(2)	(3)
288.	MHP ... 59 FUNGUS Drpos	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
289.	MHP ... 60 HORMODEC Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
290.	MHP ... 61 VARICELLA Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
291.	MHP ... 62 URTISOL Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
292.	MHP ... 63 PARKINSOL Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
293.	HEART COMPLEX Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
294.	ALFALFA TONIC Syrup	Deferred for <ul style="list-style-type: none"> • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
295.	ASHOKA Syrup	Deferred for <ul style="list-style-type: none"> • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
296.	BRYCOVIT Syrup	Deferred for <ul style="list-style-type: none"> • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
297.	GERD Syrup	Deferred for <ul style="list-style-type: none"> • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
298.	HAPAMAG Syrup	Deferred for <ul style="list-style-type: none"> • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
299.	HERSTEL Syrup	Deferred for <ul style="list-style-type: none"> • Change of brand name

S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
300.	LAXI Syrup	Deferred for <ul style="list-style-type: none"> Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). The applied formulation contains Bryonia in 3x and Nux vomica in 3x preapartion which is toxic and revise the potency with 6x or above.
301.	PANTOUX Syrup	Deferred for <ul style="list-style-type: none"> Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). The applied formulation contains Bryonia 3x and Belladonna in 3x preapartion which is toxic and revise the potency with 6x or above.
302.	RENECAL Syrup	Deferred for <ul style="list-style-type: none"> Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
303.	VOMEZ Syrup	Deferred for <ul style="list-style-type: none"> Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
304.	ACIDIN –C Syrup	Deferred for <ul style="list-style-type: none"> Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
305.	GINKGO BILOBA TONIC Syrup	Deferred for <ul style="list-style-type: none"> Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
306.	JAM E RAHAT Syrup	Deferred for <ul style="list-style-type: none"> Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). The applied formulation contains Aconite in 3x preapartion which is toxic and revise the potency with 6x or above.
307.	MHP FEVER SYRUP Syrup	Deferred for <ul style="list-style-type: none"> Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). The applied formulation contains Aconite in 3x and Belladonna in 3x preapartion which is toxic and revise the potency with 6x or above.
308.	MHP GASTRIC SYRUP Syrup	Deferred for <ul style="list-style-type: none"> Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). The applied formulation contains Aconite in 3x preapartion which is toxic and revise the potency with 6x or above.
309.	MHP COUGH SYRUP Syrup	Deferred for <ul style="list-style-type: none"> Change of brand name

S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). The applied formulation contains Broyonia and Belladonna in 3x mother tincture preparation which is toxic and revise the potency with 6x or above.
310.	MHP DIARRHEA SYRUP Syrup	Deferred for <ul style="list-style-type: none"> Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
311.	MHP TONSITRIX SYRUP Syrup	Deferred for <ul style="list-style-type: none"> Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
312.	FIBROLEC MALT Syrup	Deferred for <ul style="list-style-type: none"> Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
313.	INFACURE COLIC DROPS Drops	Deferred for <ul style="list-style-type: none"> Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
314.	MULLEIN EAR DROPS Drops	Deferred for <ul style="list-style-type: none"> Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). The applied formulation contains Aconite and Belladonna in mother tincture preparation which is toxic and revise the potency with 6x or above.
315.	PEDITRON GRIPE WATER Syrup	Deferred for <ul style="list-style-type: none"> Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
316.	PLANTAGO DENTAL REMEDY Drops	Deferred for <ul style="list-style-type: none"> Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). The applied formulation contains Aconite in 3x and Belladonna in mother tincture preparation which is toxic and revise the potency with 6x or above.
317.	SINUX NASAL SPRAY Spray	Deferred for <ul style="list-style-type: none"> Confirmation/Availability of Homeopathic Nasal Spray section Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
318.	SHARBAT E FAULAD Syrup	Deferred for <ul style="list-style-type: none"> Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
319.	DYROSOL Syrup	Deferred for <ul style="list-style-type: none"> Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
320.	Diaracin Drops	Deferred for

S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
321.	Brenol Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
322.	Venrol Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). • The applied formulation contains Psorinum which is poisonous revise /clarification regarding formulation is required
323.	Verminal Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
324.	Sleepnex Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
325.	Semone Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). • The applied formulation contains Nux vomica in 3x potency which is toxic and revise the formulation with potency of 6x or above
326.	Baby Tonic Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
327.	Yohimbitone Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
328.	Diagoline Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
329.	Eyetis Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
330.	Rheumacin Drops	Deferred for

S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
331.	Mensee Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
332.	Lactocin Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
333.	Pleuragin Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
334.	Easy Birth Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
335.	Respicin Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
336.	Episinium Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
337.	Strumeel Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
338.	Tonsilex Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
339.	PILES FAR Powder	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
340.	Scialgin Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).

S.No	Brand name	Decision
(1)	(2)	(3)
341.	Preshole Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
342.	Redcor Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
343.	Reno Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
344.	Sinuse Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
345.	Pilex Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
346.	Alfasy Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
347.	Paralysin Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
348.	Veratrum Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
349.	Vertigone Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
350.	Baresin Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
351.	Geritax Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name

S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
352.	Ulcerine Drops	Deferred for <ul style="list-style-type: none"> Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
353.	Steron Drops	Deferred for <ul style="list-style-type: none"> Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
354.	Nervita Drops	Deferred for <ul style="list-style-type: none"> Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
355.	Antifebrol Drops	Deferred for <ul style="list-style-type: none"> Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
356.	Barsal Drops	Deferred for <ul style="list-style-type: none"> Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). The applied formulation contains poisonous preparation Psorinium revise/clarification regarding the formulation is required
357.	Womenlex Drops	Deferred for <ul style="list-style-type: none"> Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
358.	Headexine Drops	Deferred for <ul style="list-style-type: none"> Confirmation/Availability of Homeopathic Drops Section. Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
359.	Menstone Drops	Deferred for <ul style="list-style-type: none"> Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
360.	Kalsolene Drops	Deferred for <ul style="list-style-type: none"> Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
361.	B...Tax Lotion	Deferred for <ul style="list-style-type: none"> Confirmation/Availability of Homeopathic Drops Section. Change of brand name

S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). The applied formulation contains rhus tox in mother tincture potency which is toxic and revise the formulation with potency of 6x or above
362.	Rheumalex Drops	Deferred for <ul style="list-style-type: none"> Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). The applied formulation contains Berberis vulgaris in 3x potency which is toxic and revise the formulation with potency of 6x or above
363.	Arteria Drops	Deferred for <ul style="list-style-type: none"> Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
364.	Calculin Drops	Deferred for <ul style="list-style-type: none"> Confirmation/Availability of Homeopathic Drops Section. Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
365.	Uritone Drops	Deferred for <ul style="list-style-type: none"> Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). The applied formulation contains Berberis vulgaris in 3x potency which is toxic and revise the formulation with potency of 6x or above
366.	Epigo Drops	Deferred for <ul style="list-style-type: none"> Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Teasting certifacte/evidence is required that source of sarcodes(TSE,BSE free)
367.	Vomitis Drops	Deferred for <ul style="list-style-type: none"> Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
368.	Mouthogin Drops	Deferred for <ul style="list-style-type: none"> Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
369.	Jenitone Drops	Deferred for <ul style="list-style-type: none"> Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
370.	Heptone Drops	Deferred for <ul style="list-style-type: none"> Confirmation/Availability of Homeopathic Drops Section. Change of brand name

S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
371.	Gripsin Drops	Deferred for <ul style="list-style-type: none"> Confirmation/Availability of Homeopathic Drops Section. Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). The applied formulation contains Bryonia alba in 2x potency which is toxic and revise the formulation with potency of 6x or above
372.	Hernex Drops	Deferred for <ul style="list-style-type: none"> Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). The applied formulation contains Nux vomica in 3x potency which is toxic and revise the formulation with potency of 6x or above
373.	Cardina Drops	Deferred for <ul style="list-style-type: none"> Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
374.	Tansol Drops	Deferred for <ul style="list-style-type: none"> Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
375.	Rheumata Drops	Deferred for <ul style="list-style-type: none"> Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
376.	Cancerolene Drops	Deferred for <ul style="list-style-type: none"> Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
377.	Francy Drops	Deferred for <ul style="list-style-type: none"> Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
378.	Lekreen Drops	Deferred for <ul style="list-style-type: none"> Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
379.	Deafol Drops	Deferred for <ul style="list-style-type: none"> Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
380.	Enura Drops	Deferred for <ul style="list-style-type: none"> Confirmation/Availability of Homeopathic Drops Section.

S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
381.	Blut Drops	Deferred for <ul style="list-style-type: none"> Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
382.	Psorineel Drops	Deferred for <ul style="list-style-type: none"> Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
383.	Kidsal Drops	Deferred for <ul style="list-style-type: none"> Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
384.	Spermatorrhin Drops	Deferred for <ul style="list-style-type: none"> Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
385.	Gelsemium Drops	Deferred for <ul style="list-style-type: none"> Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). The applied formulation contains Rhus tox 4x potency which is toxic and revise the formulation with potency of 6x and above
386.	Jaitol Drops	Deferred for <ul style="list-style-type: none"> Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
387.	Intestinal Drops	Deferred for <ul style="list-style-type: none"> Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). The applied formulation contains Bryonia in 4x potency which is toxic and revise the formulation with potency of 6x and above
388.	Stomolene Drops	Deferred for <ul style="list-style-type: none"> Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
389.	Skinex Drops	Deferred for <ul style="list-style-type: none"> Confirmation/Availability of Homeopathic Drops Section. Change of brand name Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). The applied formulation contains Rhus tox and Graphite in 4x and 3x potency which is toxic and revise the formulation with potency of 6x and above

S.No	Brand name	Decision
(1)	(2)	(3)
390.	Shifanole Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
391.	Baimisal Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
392.	Colicin Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
393.	Facit Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
394.	Gastru Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
395.	Pelone Drops	Deferred for <ul style="list-style-type: none"> • Confirmation/Availability of Homeopathic Drops Section. • Change of brand name • Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
M/s Mektum Homoeo Pharma, Karachi		
396.	T#57	Deferred for further deliberation
397.	Digi Mek Syrup	Deferred for further deliberation
398.	Gyno Zin Syrup	Deferred for further deliberation
399.	Gynofex Syrup	Deferred for further deliberation
400.	Mek-Safi Syrup	Deferred for further deliberation
M/s MS Laboratories (Homoeo Division), St.No.28, Nisar Colony Industrial Area, Samanabad, Faisalabad (E. No.00551)		
401.	Antipyrinum Q	Deferred for Homeopathic monograph of Phenazone is required
402.	Apis Mellifica Q	Deferred for evidence of sarcoce testing (TSE BSE Ecoli) free is required
403.	Cantharis Vesicatoria Q	Dfereed for sarcode testing of TSE,BSE is required
404.	Cola Q	Deferred for Homeopathic monograph of cola is required
405.	Fel Tauri Q(EHPI)	Deferred for sarcode testing (TSE,BSE is required)
406.	Formica Rufa Q	Deferred for sarcode testing (TSE,BSE is required)
407.	Naphthalinum Q=1CH	Deferred for Homeopathic mnograph of Naphthalinium is required
408.	Sepia Q	Deferred for sarcode testing(TSE,BSE) is required
M/s Pak German Pharma, Plot No. 39-A, R-3 Industrial Estate, Gadoon Amzai, Swabi (E. No.00723)		
409.	Alfalfa China Ginseng syrup	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
410.	Carbo Vege Syrup	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).

S.No	Brand name	Decision
(1)	(2)	(3)
411.	Baby Too Syrup	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
412.	Sticta Syrup	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
413.	Khoon Safi syrup	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
414.	Stone Crasher syrup	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
415.	Shaticoral syrup	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
416.	Phyto Fort syrup	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
417.	Sandrol syrup	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
418.	Energex syrup	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
419.	Santo Nin syrup	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
420.	Secale Nin syrup	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
421.	Joint Flex syrup	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
422.	Damiana drops	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
423.	Carbo Vege drops	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
424.	Hamamelis drops	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
425.	Testa ovarum drops	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed

S.No	Brand name	Decision
(1)	(2)	(3)
		Evidence of source that should free from sarcodes(TSE,BSE and E coli)
426.	Kali Phos drops	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
427.	Berberis drops	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed Raise the strength of Belladonna from 3x to 6x or above
428.	Abdamee tablet	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
429.	Agnus Plus tablet	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
430.	Calcaria Plus tablet	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
431.	UP Calcium tablet	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
432.	Luteum Tin capsule	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
433.	Leucorrhoea Folaad capsule	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
434.	Acid Phos capsule	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
435.	Morgan capsule	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
436.	B.H capsule	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
437.	Sperma capsule	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
438.	Shifa e Naswa Drops (External use)	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
439.	Ferrum Drops	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
440.	Gastrozyme Syrup	Deferred for

S.No	Brand name	Decision
(1)	(2)	(3)
		Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
441.	Ashoka Syrup	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
442.	Night capsule	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
443.	Tonsil Drops	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
444.	Nux Drops	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
445.	Calciron Syrup	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
446.	Kasrat Syrup	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
447.	Cystonil Capsule	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
448.	Amenor Capsule	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record)
449.	No prol Capsule	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
450.	Arthro Drops	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
451.	Hydrocot Syrup	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
452.	Fertile Capsule	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
453.	Ova agnus Tablet	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
454.	Symphori Syrup	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
455.	HBP Drops	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).

S.No	Brand name	Decision
(1)	(2)	(3)
456.	No abortion Syrup	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
457.	Haemoglobin Syrup	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
458.	Faulad Syrup	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
459.	Bed wetting Drops	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
460.	Appetite Drops	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
461.	Freckles acne Drops	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
462.	Collins Drops	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
463.	Male Sex Drops	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
464.	Kidney Drops	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
M/s. Paul Brooks Homoeo Labs, Plot No. A-69, S.I.T.E., Super Highway Phase-I, Karachi (E. No.0088)		
465.	Rulcid Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence ,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
466.	Antifat Plus Capsule	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence ,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
467.	Ginseng 1x Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence ,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly appreciated the services of division of health and OTC and

S.No	Brand name	Decision
(1)	(2)	(3)
		decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
468.	Itcho Cream	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence ,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
469.	Kracko Cream	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence ,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
470.	Vitigo Ointment	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence ,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
471.	Gandhakeen Cream	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence ,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
472.	V.Care Cream	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence ,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
473.	Nozema Ointment	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence ,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
474.	Markonil Cream	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence ,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
475.	Arsenicum Album 30C Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence ,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.

S.No	Brand name	Decision
(1)	(2)	(3)
476.	Caricon Capsule	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence ,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
477.	Immune Elderbarry Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence ,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
478.	Kali Plex Drops	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence ,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
479.	Malca Drops	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence ,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
480.	Podina Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence ,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
481.	Vital C Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence ,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
482.	Colic Drop	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence ,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
483.	Anti Krack Cream	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence ,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
484.	Gasgon Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent

S.No	Brand name	Decision
(1)	(2)	(3)
		preparation of their FIFO list, the division has been evaluating and processing files. Hence ,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
485.	Coffic Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence ,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
486.	Fasto Gel	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence ,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
487.	Pileeno Ointment	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence ,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
488.	Pileeno Capsule	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence ,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
489.	Leuconil Capsule	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence ,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
490.	Maledo Capsule	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence ,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
491.	Ginkgo Stress Relief Oral Liquid	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence ,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
492.	Spermax Capsule	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence ,there are chances that some product applications were disposed of but still their names are available in the FIFO list.

S.No	Brand name	Decision
(1)	(2)	(3)
		Accordingly appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
M/s Roots Pharma (Pvt) Ltd., Plot No.602, Sunder Industrial Estate, Lahore (E. No.00553)		
493.	Roots STONIL Drops	Deferred for rationality, justification and safety profile of product is required
494.	Roots CoffChil Drops	Deferred for change of brand name
495.	Roots MSL VITA M SYRUP	Deferred for rationality, justification and safety profile of product is required
496.	Roots MSL MediPlex Syru	Deferred for change of brand name
497.	Roots AA Calbet-C Tablet	Deferred for change of brand name
498.	Roots AA Cuf-No Plus Syrup	Deferred for change of brand name
499.	Roots BIO FEVER Syru	Deferred for change of brand name
500.	Roots Cough Max Syrup	Deferred for change of brand name
501.	Roots GASTRO MAX Syrup	Deferred for rationality, justification and safety profile of product is required
502.	Roots METI CHOR Syrup	Deferred for change of brand name
M/s Rose Homeo Research Laboratories, Plot No. 75-78, Small Industrial Estate, Sheikhabad, Takhtbhi Road, Charsadda (E. No.00932)		
503.	Digitalis Purpurea ø	Deferred for homeopathic monograph of Digitalis purpurea along with method of preparation of Mother tincture
504.	Eupatorium Perfoliatum Dilution	Deferred for specification of applied product is required
505.	Gun Powder	Deferred for specification of applied product is required clarification regarding handling source, storage and safety profile of gun powder is required
506.	Hekla Lava	Deferred for specification of applied product is required clarification regarding handling source, storage and safety profile of Hekla lava is required
507.	Hepar Sulphure	Deferred for specification of applied product is required
508.	Ignata Amara	Deferred for specification of applied product is required
509.	Insulin	Deferred for sarcode testing (TSE,BSE and Ecoli) is required
510.	Ipecacuanha	Deferred for specification of applied product is required
511.	Iris	Deferred for specification of applied product is required
512.	Kali bichromicum	Deferred for specification of applied product is required
513.	Kalma Latifolia	Deferred for specification of applied product is required
514.	Femafit	Deferred for Clarification regarding dosage form of applied product, Specification of active ingredients and 10 years sales and distribution data of applied combination product
515.	Gout Cure	Deferred for Clarification regarding dosage form of applied product, Specification of active ingredients and 10 years sales and distribution data of applied combination product
516.	Fibro Cyst	Deferred for Clarification regarding dosage form of applied product, Specification of active ingredients and 10 years sales and distribution data of applied combination product
517.	Justicia Adhatoda	Deferred for specification of applied product is required
518.	Kreosotum	Deferred for specification of applied product is required
519.	Kali Bromatum	Deferred for specification of applied product is required
520.	Kali carbonicum	Deferred for specification of applied product is required
521.	Kali Muriaticum	Deferred for specification of applied product is required
522.	kali Arsenicosum	Deferred for specification of applied product is required
523.	Lemna Minor	Deferred for specification of applied product is required

S.No	Brand name	Decision
(1)	(2)	(3)
524.	Lithium Benzoicum	Deferred for specification of applied product is required
525.	Ledum Palustre	Deferred for specification of applied product is required
526.	Lac Caninum	Deferred for specification of applied product is required
527.	Moschus	Deferred for specification of applied product is required
528.	Murex Purpurea	Deferred for specification of applied product is required
529.	NAPHTHALINUM	Deferred for Homeopathic monograph of Naphthalinum is required
530.	Natrum Arsenicum	Deferred for specification of applied product is required
531.	Natrum Carbonicum	Deferred for specification of applied product is required
532.	Natrum Phosphoricum	Deferred for specification of applied product is required
533.	Natrum Salicylicum	Deferred for specification of applied product is required
534.	Natrum Sulphuratum	Deferred for specification of applied product is required
535.	Ocimum Canum	Deferred for specification of applied product is required
536.	Onosmodium Virginianum	Deferred for specification of applied product is required
537.	Pichi	Deferred for specification of applied product is required
538.	Plantago Major	Deferred for specification of applied product is required
539.	Plumbum Metallicum	Deferred for specification of applied product is required
540.	Podophyllum	Deferred for specification of applied product is required
541.	Pothos Foetidus	Deferred for specification of applied product is required
542.	Pulsatilla Nigricans	Deferred for specification of applied product is required
543.	Pinus Sylvestris	Deferred for specification of applied product is required
544.	Pituitarium	Deferred for sarcode testing(TSE,BSE,Ecoli) is required
545.	Pix Liquida	Deferred for specification of applied product is required
546.	Prostate Gland	Deferred for sarcode testing(TSE,BSE,Ecoli) is required
547.	Ranunculus Bulbosus	Deferred for specification of applied product is required
548.	Paeonia Officinalis	Deferred for specification of applied product is required
549.	Paraffinum Diluting by 90% alcohol	Deferred for specification of applied product is required
550.	Petroleum	Deferred for specification of applied product is required
551.	Phosphorus	Deferred for specification of applied product is required
552.	Malaria Officinalis	Deferred for specification of applied product is required
553.	Manganum Aceticum	Deferred for specification of applied product is required
554.	Mephitis Mephitis Dilution	Deferred for specification of applied product is required
555.	Natrum Salicylicum Dilution	Deferred for specification of applied product is required
556.	Mezereum	Deferred for specification of applied product is required
557.	Happy Move 20ml	Deferred for submission of 10 years data of sales and distribution of applied combination product
558.	Ginkgo-G 120ml 250 ml	Deferred for submission of 10 years data of sales and distribution of applied combination product
559.	Artemet 20ml	Deferred for submission of 10 years data of sales and distribution of applied combination product
560.	Pilomorm 20ml	Deferred for submission of 10 years data of sales and distribution of applied combination product
561.	Ferrum Hony 120ml	Deferred for submission of 10 years data of sales and distribution of applied combination product
562.	Bell-O-Nion 20ml	Deferred for submission of 10 years data of sales and distribution of applied combination product
563.	Parkinsonism 20ml	Deferred for submission of 10 years data of sales and distribution of applied combination product
M/s Sadiq Pharma (Pvt) Ltd., Moza Kotli Rawalpindi Road, Jand (E. No.00499)		
564.	Rani Khet Cure 1X Liquid	Deferred for change of brand name
565.	Colcogest Fort 1X Liquid	Deferred for change of brand name
566.	High Gest 30X Powder	Deferred for change of brand name
567.	OTC 1X Liquid	Deferred for change of brand name
568.	Magic OTC 3x Liquid	Deferred for change of brand name
569.	Arnica Gold 30 Liquid	Deferred for change of brand name
M/s Sante Graine de Vie Pharma (Pvt) Ltd., Plot No. 1-A, Engineering Zone, Value Addition City Khurrianwala, Faisalabad (E. No.00806)		
570.	PUR ESTOMAC TABLET	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).

S.No	Brand name	Decision
(1)	(2)	(3)
571.	PUR TONSIL Tab.	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
572.	PPUR VISION TABLET	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
573.	CONT.LECORR TABLET	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
574.	HAIR VITA TABLET	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
575.	CONT.HEMORR TABLET	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
576.	BEDPLASSEN TABLET	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
577.	CONT. STOM TABLET	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
578.	CONT. DEPRESSIVE TABLET	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
579.	PUR DYSMENORR Tablet	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
580.	CONT. ALLERGIN Tab.	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
581.	VOORMAN Tab.	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
582.	PROST. KEITH Tab.	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
583.	REIN STEIN Tab.	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
584.	MENOZEIT Tab.	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
585.	BIO+NO.1	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
586.	BIO+NO.2	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
587.	BIO+NO.3	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
588.	BIO+NO.4	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
589.	BIO+NO.5	Deferred for

S.No	Brand name	Decision
(1)	(2)	(3)
		Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record)
590.	BIO+NO.6	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
591.	BIO+NO.7	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
592.	BIO+NO.8	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
593.	BIO+NO.9	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
594.	BIO+NO11	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
595.	BIO+NO.20	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
596.	BIO+NO.22	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
597.	BIO+NO.25	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
598.	BIO+NO.27	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
599.	BIO+NO.28	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
600.	HYPERT.EX TABLET	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
601.	FORT IS Tab.	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
602.	HAUTO GIN TABLET	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
603.	HEPA PRO TABLET	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
604.	PHYTOLACCA BERRY SLIM Tab.	Deferred for change of brand name
605.	ALFALFA SYRUP	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
606.	BRONCHCARE SYRUP	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).

S.No	Brand name	Decision
(1)	(2)	(3)
607.	Grownic Syrup	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
608.	FERONISA SYRUP	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
609.	Rein Stein Drops	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
610.	CONT.HEMORR DROPS	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
611.	RHUMATISMO DROPS	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
612.	PUR ESTOMAC DROPS Each 20ml contains	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
613.	VOORMAN DROPS	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
M/s Sonexo Homoeo 15 Lakhodher Industrial Zone, Turkey Road, Lahore (E. No.00758)		
614.	Sonexo's Robina Pseud	Deferred for sarcode testing (TSE,BSe,Ecoli) is required
615.	Sonexo's Sepia	Deferred for sarcode testing (TSE,BSe,Ecoli) is required
M/s TS Laboratories, [Homeopathic Human] 5-Km Makkuana Bypass, Khurianwala, Faisalabad-Pakistan (E. No. 00640)		
616.	TS CRATAEGUS POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
617.	TS CARBO VEGETABILIS POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
618.	TS CIMICIFUGA RACEMOSA POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
619.	TS SABINA POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
620.	TS SARSAPARILLA POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
621.	TS POLYGALA SENEGA POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
622.	TS SEPIA POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
623.	TS CINA POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
624.	TS SYZYGIUM CUMINII POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
625.	TS STERCULIA POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
626.	TS SOLIDAGO VIRGAUREA POTENCY Solidago VirgaureaPotencies Solidago Virgaurea(EHPI) (EHPI Specifications)	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
627.	TS COLLINSONIA POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
628.	TS COLOCYNTHIS POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
629.	TS CONVALLARIA POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
630.	TS THYMOL Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
631.	TS SABADILLA POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product



S.No	Brand name	Decision
(1)	(2)	(3)
632.	TS COLCHICUM POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
633.	TS CAMPHOR POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
634.	TS NUX VOMICA POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
635.	TS ALSTONIA SCHOLARS POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
636.	TS EUCALYPTUS GLOBULUS Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
637.	TS GENTIANA LUTEA Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
638.	TS HELIANTHUS ANNUS Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
639.	TS HYDRASTIS CANADENSIS Q Each ml contains HYDRASTIS CANADENSIS(EHPI)... Ø	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
640.	TS WITHANIA SOMNIFERA POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
641.	TS TARAXACUM POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
642.	TS ORNITHOGALUM UMBELLATUM POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
643.	TS THUJA POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
644.	TS PULSATILLA POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
645.	TS ARSENICUM ALBUM POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
646.	TS ACIDUM BENZOICUM Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
647.	TS MENTHA PIPERATA Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
648.	TS CHIONANTHUS VERGINICA Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
649.	TS SELENIUM POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
650.	TS TERMINALIA ARJUNA POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
651.	TS VALERIANA OFFICINALIS...Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
652.	TS ZINGIBER OFFICANALE Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
653.	TS GOSSYPIUM HERBACEUM Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
654.	TS ALLIUM CEPA Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
655.	TS SARACA INDICA Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
656.	TS CHAMOMILLA Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
657.	TS CHELIDONIUM MAJUS Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
658.	TS MORINGA OLIFERA Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
659.	TS PAEONIA OFFICANALIS Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
660.	TS PIPER NIGRUM Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
661.	TS RICINUS COMMUNIS Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
662.	TS AMMI VISNAGA POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
663.	TS ARGENTUM NITRICUM POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
664.	TS PASSIFLORA POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
665.	TS ABIES NIGRA POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product

S.No	Brand name	Decision
(1)	(2)	(3)
666.	TS RAUWOLFIA SERPENTIN POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
667.	TS CINNAMONUM POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
668.	TS RHUS TOXICODENDRON POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
669.	TS RUMEX CRISPUS POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
670.	TS BERBERIS VULGARIS POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
671.	TS BRYONIA ALBA POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
672.	TS BELLADONA POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
673.	TS OPIUM POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
674.	TS ROBINA PSELLDACACIA POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
675.	TS RUTA GRAVEOLENS POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
676.	TS SANGUINARIA CANADENSIS POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
677.	TS SPONGIA TOSTA POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
678.	TS STAPHYSAGRIA POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
679.	TS PHYSOSTIGMA VENENOSUM Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
680.	TS RAPHANUS SATIVUS Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
681.	TS NUPHER LUTEUM Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
682.	TS ORIGANUM MAJORANA Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
683.	TS PAREIRA BRAVA Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
684.	TS CAPSICUM ANNUM Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
685.	TS BAPTISIA TINCTORIA Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
686.	TS BERBERIS AQUIFOLIUM Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
687.	TS CALENDULA OFFICINALIS Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
688.	TS CARUM CARVI Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
689.	TS SENEIO AUREUS Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
690.	TS SLAIX NIGRA Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
691.	TS RUBIA TINCTORIA Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
692.	TS SCUTELLARIA LATERIFLORA Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
693.	TS SABAL SERRULATA Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
694.	TS FRAXINUS AMERICANA Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
695.	TS GINKGO BILOBA Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
696.	TS FILIX MAS Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
697.	TS EUPATORIUM PERFOLIATUM Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
698.	TS EPIGAEA REPENS Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
699.	TS APIS MELLIFICA Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
700.	TS BADIAGA Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
701.	TS BACOPA MONNIERI Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section


S.No	Brand name	Decision
(1)	(2)	(3)
702.	TS AZADIRACHTA INDICA Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
703.	TS ASAFOETIDA Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
704.	TS CASCARA SAGRADA Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
705.	TS COCCULUS INDICUS Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
706.	TS CHELONE GLABRA Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
707.	TS CEANOTHUS AMERICANUS Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
708.	TS CAULOPHYLLUM THALICTROIDES Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
709.	TS AGNUS CASTUS Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
710.	TS ALETRIS FARINOSA Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
711.	TS AMBRA GRISEA Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
712.	TS ANGUSTURA VERA Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
713.	TS ABSINTHIUM Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
714.	TS GLYCYRRHIZA GLABRA Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
715.	TS GINSENG Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
716.	TS GUAIAECUM Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
717.	TS HEDERA HELIX Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
718.	TS NASTURTIUM AQUATICUM Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
719.	TS SOLANUM NIGRUM Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
720.	TS SYMPHYTUM OFFICINALE Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
721.	TS URTICA URENS Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
722.	TS YOHIMBINUM Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
723.	TS THLASPI BURSA PASTORIS Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
724.	TS COCCUS CACTI Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
725.	TS DULCAMARA Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
726.	TS CROCUS SATIVUS Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
727.	TS CORIANDRUM SATIVUM Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
728.	TS COFFEA CRUDA Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
729.	TS THYMOL POTENCY	Deferred for Clarification is required regarding the dosage form of applied product along with availability of section
730.	TS VALERIANA OFFICINALIS POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
731.	TS ZINGIBER OFFICINALE POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
732.	TS GOSSYPIUM HERBACEUM POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
733.	TS VIBURNUM OPULUS POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
734.	TS MENTHA PIPERATA POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
735.	TS MORINGA OLIFERA POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product

S.No	Brand name	Decision
(1)	(2)	(3)
736.	TS PAEONIA OFFICINALIS POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
737.	TS PIPER NIGRUM POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
738.	TS RICINUS COMMUNIS POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
739.	TS DROSEROTA ROTUNDIFOLIA POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
740.	TS SOLANUM DULCAMARA POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
741.	TS ECHINACEA ANGUSTIFOLIA POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
742.	TS EUPHRASIA OFFICINALIS POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
743.	TS FUCUS VES POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
744.	TS ACIDUM BENZOICUM POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
745.	TS ALLIUM CEPA POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
746.	TS ASHOKA POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
747.	TS CHAMOMILLA POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
748.	TS CHELIDONIUM MAJUS POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
749.	TS CHIONANTHUS VERGINICAL POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
750.	TS EUCALYPTUS GLOBULUS POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
751.	TS GENTIANA LUTEA POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
752.	TS HELIANTHUS ANNUUS POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
753.	TS HYDRASTIS CANADENSIS POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
754.	TS ROBINIA PSEUDACACIA Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
755.	TS RUTA GRAVEOLENS Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
756.	TS SANGUINARIA CANADENSIS Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
757.	TS SPONGIA TOSTA Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
758.	TS STAPHYSAGRIA Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
759.	TS CINCHONA CHINA Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
760.	TS CROTON TIGLIUM Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
761.	TS DAMIANA Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
762.	TS DIGITALIS PURPUREA Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
763.	TS DIOSCOREA VILLOSA Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
764.	TS COLOCYCIUM Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
765.	TS COLLINSONIA CANDENSIS Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
766.	TS COLOCYNTHIS Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
767.	TS CONVALLARIA Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
768.	TS CRATAEGUS OXYACANTYHA Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
769.	TS TEUCRIUM MARUM POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
770.	TS USNEA BARBATA POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product




S.No	Brand name	Decision
(1)	(2)	(3)
771.	TS VERATRUM ALBUM POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
772.	TS VERATRUM VIRIDE POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
773.	TS TRIBULUS TERRESTRIS POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
774.	TS CHIMAPHILA UMBELLATA POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
775.	TS CARDUUS MARIANUS POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
776.	TS CAULOPHYLLUM THALICTROIDES POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
777.	TS ACIDUM PHOSPHORICUM POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
778.	TS AESCULUS HIPPOCASTANUM POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
779.	TS ACIDUM PHOSPHORICUM Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
780.	TS AESCULUS HIPPOCASTANUM Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
781.	TS CARDUUS MARIANUS Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
782.	TS CAULOPHYLLUM THALICTROIDES Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
783.	TS CHIMAPHILA UMBELLATA Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
784.	TS GELSEMIUM SEMPERVIRENS Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
785.	TS GUAIAVUM OFFICINALE Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
786.	TS HAMAMELIS VIRGINICA Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
787.	TS PLANTAGO MAJOR Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
788.	TS PODOPHYLLUM PELTATUM Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
789.	TS CINCHONA CHINA POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
790.	TS CROTON TIGLUM POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
791.	TS DAMIANA POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
792.	TS DIGITALIS PURPUREA POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
793.	TS DIOSCORIA VILLOSA POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
794.	TS BELLADONA Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
795.	TS BERBERIS VULGARIS Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
796.	TS BRYONIA ALBA Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
797.	TS OPIUM Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
798.	TS ORNITHOGALUM Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
799.	TS ANACARDIUM Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
800.	TS ARNICA MONTANA Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
801.	TS ARTEMISIA VULGARIS Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
802.	TS AVENA SATIVA Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
803.	TS ABIES NIGRA Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
804.	TS TRIBULUS TERRESTRIS Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
805.	TS TEUCRIUM MARUM Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section

S.No	Brand name	Decision
(1)	(2)	(3)
806.	TS USNEA BARBATA Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
807.	TS VERATRUM ALBUM Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
808.	TS VERATRUM VIRIDE Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
809.	TS VIBURNUM OPULUS Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
810.	TS PASSIFLORA INCARNATA Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
811.	TS PULSATILLA Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
812.	TS RAWOLFIA SERPENTINA Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
813.	TS RHUS TOXICODENDRON	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
814.	TS RUMEX CRISPUS Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
815.	TS ABROTANUM Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
816.	TS ACONITUM Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
817.	TS AETHUSA CYNAPIUM Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
818.	TS ALFALFA Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
819.	TS ALLIUM SATIVUM Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
820.	TS GELSEMIUM SEMPERVIRENS POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
821.	TS GUAIACUM OFFICINALE POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
822.	TS HAMAMELIS VIRGINICA POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
823.	TS PLANTAGO MAJOR POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
824.	TS PODOPHYLLUM PELTATUM POTENCY	Deferred for the Clarification is required regarding the potencies /Serial Dilution of applied product
825.	TS CAMPHOR OFFICINALIS Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
826.	TS CARBO VEGETABILIS Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
827.	TS CIMICIFUGA RACEMOSA Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
828.	TS CINA Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
829.	TS CINNAMONUM ZYLONICUM Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
830.	TS ARSENICUM ALBUM Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
831.	TS ASHWAGANDHA Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
832.	TS SEPIA Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
833.	TS STERCULIA Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
834.	TS SELENIUM Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
835.	TS DROSEROTA ROTUNDIFOLIA Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
836.	TS DULCAMARA Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
837.	TS ECHINACEA ANGUSTIFOLIA Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
838.	TS EUPHRASIA OFFICINALIS Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
839.	TS FUCUS VESICULOSUS Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
840.	TS SUGER CONTROL SYRUP	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).




S.No	Brand name	Decision
(1)	(2)	(3)
841.	TS BRAIN TONIC SYRUP	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
842.	TS BABY VIT SYRUP	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
843.	TS THANDAK SYRUP	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
844.	TS PAIN OFF SYRUP	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
845.	TS HBP SYRUP	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
846.	TS COUGH DRY POWDER	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
847.	TS VITA PLUS DRY POWDER	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
848.	TS CALCIUM PLUS DRY POWDER	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
849.	TS NISA HAIR OIL	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
850.	TS GYNO REX SYRUP	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
851.	TS MUSAFI KHOON SYRUP	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
852.	TS BLOOD SYRUP	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
853.	TS COLIREX SYRUP	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
854.	TS VOMINAL SYRUP	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
855.	TS DAMIANA PLUS SYRUP	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).



S.No	Brand name	Decision
(1)	(2)	(3)
856.	TS VITA PLUS SYRUP	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
857.	TS DROP 7	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Confirmation regarding availability of Drop (Homeopathic section)
858.	TS DROP 8	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Confirmation regarding availability of Drop (Homeopathic section)
859.	TS DROP 9	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Confirmation regarding availability of Drop (Homeopathic section)
860.	TS DROP 10	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Confirmation regarding availability of Drop (Homeopathic section)
861.	TS DROP 11	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Confirmation regarding availability of Drop (Homeopathic section)
862.	TS DROP 12	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Confirmation regarding availability of Drop (Homeopathic section)
863.	TS DROP 13	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Confirmation regarding availability of Drop (Homeopathic section)
864.	TS DROP 14	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Confirmation regarding availability of Drop (Homeopathic section)
865.	TS DROP 15	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Confirmation regarding availability of Drop (Homeopathic section)
866.	TS DROP 16	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Confirmation regarding availability of Drop (Homeopathic section)
867.	TS DROP 17	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Confirmation regarding availability of Drop (Homeopathic section)
868.	TS DROP 18	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Confirmation regarding availability of Drop (Homeopathic section)
869.	TS DROP 19	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Confirmation regarding availability of Drop (Homeopathic section)
870.	TS DROP 21	Deferred for

S.No	Brand name	Decision
(1)	(2)	(3)
		Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Confirmation regarding availability of Drop (Homeopathic section)
871.	TS DROP 22	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Confirmation regarding availability of Drop (Homeopathic section)
872.	TS DROP 23	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Confirmation regarding availability of Drop (Homeopathic section)
873.	TS THUJA Q	Deferred for the Clarification is required regarding the dosage form of applied product along with availability of section
874.	TS TOFEN LOTION	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
875.	TS D-TOX TABLET	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
876.	TS LICON -T TABLET	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
877.	TS P-NIL TABLET	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
878.	TS C-CEPA TABLET	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
879.	TS SACFEN LOTION	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
880.	TS SAFOOF MAGHALAZ KHAS JWAHRDAR	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
M/s Zam Zam Homoeo Pharma, Multan		
881.	ZM#1 GASTRIC Drops	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
882.	ZM#2 URIC FLOW Drops	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
883.	ZM#3 ALLER...Z Drops	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
884.	ZM#4 H.B.P. Drops	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
885.	ZM#5 ACNO...Z Drops	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).



S.No	Brand name	Decision
(1)	(2)	(3)
		Brand name needs to be changed
886.	ZM#6 UTRINOL Drops	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
887.	ZM#7 KIDNAL Drops	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
888.	ZM#8 CHELLICARD Drops	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
889.	ZM#9 ZLYSIS Drops	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
890.	ZM#10 SPERMA PHOS Drops	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
891.	ZM#11 PILOZAM Drops	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
892.	ZM#12 ARTHO...Z Drops	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
893.	ZM#13 SINO...Z Drops	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
894.	ZM#14 EASY FEEL Drops	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
895.	ZM#15 SULPHUR COMPOUND Drops	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
896.	ZM#16 MENORRHOEA Drops	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
897.	ZM#17 BED WETTING Drops	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
898.	ZM#18 INFEC...Z Drops	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
899.	ZM#19 BARBELLA Drops	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
900.	ZM#20 SALIX COMPOUND Drops	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).

S.No	Brand name	Decision
(1)	(2)	(3)
		Brand name needs to be changed
901.	ALFA DS SYRUP	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
902.	ALFA+GINSENG SYRUP S.F	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
903.	ALETRIS+ASHOKA SYRUP	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
904.	APPETONE SYRUP	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
905.	AVENA + SYRUP	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
906.	B.COLIC SYRUP	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
907.	BELLACEF SYRUP	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
908.	CAL...Z SYRUP	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
909.	CAPTAIN BABY TONIC SYRUP	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
910.	CATT...Z SYRUP	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
911.	CHELLICARD SYRUP	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
912.	DAMIANA+GINSENG S.F	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
913.	DERMO...Z SYRUP	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
914.	FEMO...Z SYRUP	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
915.	FERRO-Z SYRUP	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).

S.No	Brand name	Decision
(1)	(2)	(3)
		Brand name needs to be changed
916.	FLU...Z SYRUP	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
917.	GASTO VIT SYRUP	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
918.	GASTO...Z SYRUP	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
919.	GENSO FORTE SYRUP:	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
920.	HEPA...Z ELIXIR:	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
921.	KIDNO...Z SYRUP:	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
922.	KUF...Z SYRUP:	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
923.	KURCHI COMPOUND SYRUP:	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
924.	Mensocard SYRUP:	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
925.	PEPPO...Z SYRUP:	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
926.	POWER...Z SYRUP:	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
927.	RUMEX SYRUP:	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
928.	SLIM...Z SYRUP:	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
929.	TONSI COUGH SYRUP:	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
930.	VITA GLOBIN SYRUP:	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).

S.No	Brand name	Decision
(1)	(2)	(3)
		Brand name needs to be changed
931.	VITA...Z SYRUP:	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
932.	VOMITO...Z SYRUP:	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
933.	WARMO...Z SYRUP:	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
934.	ALOE SONIA ELIXIR:	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
935.	BERBE CAN ELIXIR:	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
936.	KUF RELIEF SYRUP:	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
937.	COUGH GONE SYRUP:	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
938.	ZAMZAM PLACEBO SYRUP:	Deferred for clarification regarding formulation
939.	ZAMZAM DISKETTES/ ZAMZAM ICING SUGAR	Deferred for clarification regarding formulation
940.	ZAMZAM BLANKETTES/ ZAMZAM MILK OF SUGAR	Deferred for clarification regarding formulation
941.	DENTO...Z LOTION:	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
942.	MOUTH CURE LOTION:	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
943.	OTALLEIN LOTION:	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
944.	KRACK...Z OINTMENT:	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
945.	ZAMZAM BALM:	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
946.	Pain Gone Lotion:	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
947.	Pain...Z Lotion:	Deferred for

S.No	Brand name	Decision
(1)	(2)	(3)
		Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
948.	SCABO...Z Lotion:	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
949.	ZAMZAM KHARISH Lotion:	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
950.	B.P NORMAL DROPS:	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
951.	CALCO...Z DROPS:	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
952.	COCA...Z DROPS:	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
953.	INFERTO...Z DROPS:	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
954.	RAPHNUS + DROPS:	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
955.	RESCUE Oral Spray:	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
956.	SEPTI CURE DROPS:	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
957.	SPERMO...Z DROPS:	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
958.	KIDNEY WASH DROPS:	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
959.	MENOGIN TABLET:	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
960.	FEMOGIN TABLET:	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
961.	ANTIFEVER TABLET:	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
962.	ANTIPYREEN TABLET:	Deferred for

S.No	Brand name	Decision
(1)	(2)	(3)
		Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
963.	AVEGIN TABLET:	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
964.	BLEEDING CURE TABLET:	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
965.	CHOLE...Z TABLET:	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
966.	DYRO...Z TABLET:	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
967.	FERRO...Z TABLET:	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
968.	FLU...Z TABLET:	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
969.	GASTO...Z TABLET:	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
970.	HAYOCYNTH COMPOUND TABLET:	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
971.	HEPTO...Z TABLET:	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
972.	HISTA...Z TABLET:	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
973.	HYPER...Z TABLET:	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
974.	KUF...Z TABLET:	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
975.	L.B.P TABLET:	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
976.	LECI...CAL...D TABLET:	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
977.	LECOCIN TABLET:	Deferred for

S.No	Brand name	Decision
(1)	(2)	(3)
		Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
978.	MENSOGEN TABLET:	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
979.	PILOZAM TABLET:	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
980.	SALIX PLUS TABLET:	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
981.	SPERMA PHOS TABLET:	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
982.	SULPHOGEN TABLET:	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
983.	TONSO...Z TABLET:	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
984.	TYPHOGEN TABLET:	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
985.	ULSOOGEN TABLET:	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
986.	URIC FLOW TABLET:	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
987.	ZAMODOL TABLET:	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
988.	Z...DRY TABLET:	Deferred for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
Adcok Pharmaceutical (Pvt) Ltd, Lahore		
989.	Chelifer Tablet	Deferred for change of brand name
990.	Rinon Tablet	Deferred for change of brand name
991.	Calcify Tablet	Deferred for change of brand name
992.	Sacran Sachet	Deferred for change of brand name
993.	Calcif-D Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer

S.No	Brand name	Decision
(1)	(2)	(3)
		decision of the instant product application to check its status whether it has been disposed of or otherwise.
994.	Lifolac Powder	Deferred for change of brand name
995.	Sacran Syrup	Deferred for change of brand name
996.	On Life Tablet	Deferred for change of brand name
997.	Cranblex Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
998.	Gomeg Drop	Deferred for change of brand name
999.	Neo Chline Tablet	Deferred for change of brand name
1000.	Koffsafe Drops	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1001.	Magtin Tablet	Deferred for change of brand name
1002.	Rexbion Tablet	Deferred for change of brand name
1003.	Trisafe Syrup	Deferred for change of brand name
1004.	Maxfair Tablet	Deferred for change of brand name
1005.	Proneed Sachet	Deferred for change of brand name
1006.	Q-Lime Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1007.	Testron Tablet	Deferred for change of brand name
1008.	Ultra D Tablet	Deferred for change of brand name
1009.	Magtin Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1010.	Activer Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1011.	Laze-D Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and

S.No	Brand name	Decision
(1)	(2)	(3)
		subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1012.	Ripro Drops	Deferred for change of brand name
1013.	Cal-X Syrup	Deferred for change of brand name
1014.	Cof-Nix Syrup	Deferred for change of brand name
Alaq Laboratories, Lahore		
1015.	Cosatin Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1016.	Ospro D3 Drops	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1017.	Genol Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1018.	Gynotol Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1019.	Pretize Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1020.	Nt.Kuff Drops	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are

S.No	Brand name	Decision
(1)	(2)	(3)
		available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1021.	Chondroitin Plus Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1022.	Berry Mic Sachet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1023.	E Tone Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
Allomed Curatives, Islamabad		
1024.	Minto Guard Liquid	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1025.	Happy Chick Liquid	Deferred for change of brand name
1026.	Immuno Fit Liquid	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1027.	Liveron Liquid	Deferred for change of brand name
1028.	Multi Vito Max Liquid	Deferred for change of brand name
1029.	Adek Fit Liquid	Deferred for change of brand name
Alomed Curatives, Islamabad		
1030.	Super Temp Cure Oral Liquid	Deferred for change of brand name
1031.	Meat Up Powder	Deferred for change of brand name
1032.	Milk Up Powder	Deferred for change of brand name
1033.	Tempanil Liquid	Deferred for change of brand name
1034.	Bio Lizo Vit Powder	Deferred for change of brand name
1035.	Parwaz Plus Powder	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks.



S.No	Brand name	Decision
(1)	(2)	(3)
		Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1036.	Triple 5 Oral Solution	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1037.	Colic Star Liquid	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1038.	Pak Akseer Jair Nafas Powder	Deferred for change of brand name
1039.	Bone Phosphate Powder	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1040.	B-Cure Minerals Powder	Deferred for change of brand name
Anza Pharma, Lahore		
1041.	Garent-C Syrup	Deferred for the following reasons: <ul style="list-style-type: none"> Form-3, brand name and contents undertakings are unsigned/ unstamped. Fee receipt is missing.
1042.	Garent-C Tablet	Deferred for the following reasons: <ul style="list-style-type: none"> Form-3, brand name and contents undertakings are unsigned/ unstamped. Fee receipt is missing.
1043.	Garent-D Drop	Deferred for the following reasons: <ul style="list-style-type: none"> Form-3, brand name and contents undertakings are unsigned/ unstamped. Fee receipt is missing.
1044.	Kidsol Sachet	Deferred for change of brand name
1045.	Mc New Sachet	Deferred for the following reasons: <ul style="list-style-type: none"> Form-3, brand name and contents undertakings are unsigned/ unstamped. Fee receipt is missing.
1046.	Qufo Tablet	Deferred for the following reasons: <ul style="list-style-type: none"> Form-3, brand name and contents undertakings are unsigned/ unstamped. Fee receipt is missing.
1047.	Qx-Forte Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been

S.No	Brand name	Decision
(1)	(2)	(3)
		evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1048.	Calmoon Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1049.	H-D Oral Drops	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1050.	Instacal-D Tablet	Deferred for change of brand name
1051.	Tonisan Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1052.	Noni Grow Syrup	Deferred for change of brand name
1053.	Noni Grow Drops	Deferred for change of brand name
Arber Pharma, Lahore		
1054.	Glosence Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1055.	Glsence Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1056.	Super-Cal Syrup	Deferred for change of brand name
1057.	Super-Cal Tablet	Deferred for change of brand name
1058.	Osteo-5 Tablet	Deferred for change of brand name
1059.	Bio-Mv Syrup	Deferred for change of brand name
1060.	Bio-Mv Tablet	Deferred for change of brand name
1061.	Mecolax Tablet	Deferred for change of brand name
1062.	Ct Max Tablet	Deferred for change of brand name

S.No	Brand name	Decision
(1)	(2)	(3)
1063.	Ct Max Syrup	Deferred for change of brand name
1064.	Noor Colic Drops	Deferred for change of brand name
1065.	Cuf-Go Syrup	Deferred for change of brand name
1066.	Bio-Kuff Syrup	Deferred for change of brand name
1067.	Scio-Cid Syrup	Deferred for change of brand name
1068.	Enuf Supplement	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1069.	Glomom Supplement	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1070.	Nutri-M Supplement	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1071.	Suppli-M Supplement	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1072.	Wellpro Supplement	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1073.	Ovasital Sachet	Deferred for change of brand name
1074.	Ad-Plus Drops	Deferred for change of brand name
1075.	Go-Pep Drops	Deferred for change of brand name
1076.	Spirglo Tablet	Deferred for change of brand name
Arzik Laboratories, Faisalabad		
1077.	Co-Q10 Vits Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the

S.No	Brand name	Decision
(1)	(2)	(3)
		services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1078.	Bone Plus-Z Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1079.	Multi-Vit Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
Aurum Health Care, Lahore		
1080.	Fertimap Tablet	Deferred for change of brand name
1081.	Aritmove Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1082.	Deon 200Iu Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1083.	Flobac Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1084.	Calmax-D Tablet	Deferred for change of brand name
1085.	Eatio Syrup	Deferred for change of brand name
1086.	Pepice Suspension	Deferred for change of brand name
1087.	Ed-Cure Tablet	Deferred for change of brand name
1088.	Sensory Oral Liquid	Deferred for change of brand name
1089.	Natfol Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the

S.No	Brand name	Decision
(1)	(2)	(3)
		services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
Bio Classic Pharma, Lahore		
1090.	Rb Plus Capsule	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1091.	Bioplex Capsule	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
Bio Life Enterprises Nutraceuticals, Rawalpindi		
1092.	Talvit Tablet	Deferred for the following reasons: <ul style="list-style-type: none"> Form-3, brand name and contents undertakings are unsigned/ unstamped. Fee receipt is missing.
1093.	Biokin Tablet	Deferred for the following reasons: <ul style="list-style-type: none"> Form-3, brand name and contents undertakings are unsigned/ unstamped. Fee receipt is missing.
1094.	Imofer Tablet	Deferred for change of brand name
1095.	Cali + Tablet	Deferred for the following reasons: <ul style="list-style-type: none"> Form-3, brand name and contents undertakings are unsigned/ unstamped. Fee receipt is missing.
1096.	Tribul Capsule	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1097.	Tribestin Capsule	Deferred for the following reasons: <ul style="list-style-type: none"> Form-3, brand name and contents undertakings are unsigned/ unstamped. Fee receipt is missing.
1098.	Alneed Tablet	Deferred for change of brand name
1099.	Vitona Tablet	Deferred for the following reasons: <ul style="list-style-type: none"> Form-3, brand name and contents undertakings are unsigned/ unstamped. Fee receipt is missing.
1100.	Due A Drops	Deferred for change of brand name
1101.	Due D Drops	Deferred for change of brand name
1102.	Biofer Tablet	Deferred for change of brand name
1103.	Magnum-Z Gold Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are

S.No	Brand name	Decision
(1)	(2)	(3)
		available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1104.	Magnum-Z Silver Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1105.	Cal Dew Plus Tablet	Deferred for the following reasons: <ul style="list-style-type: none"> Form-3, brand name and contents undertakings are unsigned/ unstamped. Fee receipt is missing.
1106.	Cal Dew Sachet	Deferred for the following reasons: <ul style="list-style-type: none"> Form-3, brand name and contents undertakings are unsigned/ unstamped. Fee receipt is missing.
1107.	Primo Forte Tablet	Deferred for change of brand name
1108.	Four Action Syrup	Deferred for change of brand name
Bio Serve Pharma, Karachi		
1109.	Chem-Cal Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1110.	Pedistar Ors	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1111.	Pedicon Ors	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
Bless Laboratories Pvt. Ltd., Lahore		
1112.	Mythyl-F Tablet./l	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1113.	Iro-Fc Tablet	Deferred for change of brand name

S.No	Brand name	Decision
(1)	(2)	(3)
1114.	Sarmaycal-D Tablet	Deferred for change of brand name
Blossom Lab, Pvt, Ltd, Lahore		
1115.	Sharbat E Faulad Syrup	Deferred for change of brand name
1116.	Jam E Zindagi Syrup	Deferred for change of brand name
1117.	Gingko Biloba Syrup	Deferred for the following reasons: <ul style="list-style-type: none"> Form-3, brand name and contents undertakings are unsigned/unstamped. Fee receipt is missing.
1118.	Pain Stop Syrup	Deferred for change of brand name
1119.	Damialex Plus Tablet	Deferred for change of brand name
1120.	Colic Tablet	Deferred for change of brand name
1121.	Tonsilex Tablet	Deferred for change of brand name
1122.	Dialex Tablet	Deferred for change of brand name
1123.	Asthalex Tablet	Deferred for change of brand name
1124.	Calcilex Syrup	Deferred for change of brand name
1125.	Gastro Ulcer Capsule	Deferred for change of brand name
Calgan Phyto Pharma Pvt Ltd, Lahore		
1126.	Nocol Liquid Herbal Ext	Deferred for change of brand name
1127.	Stifnil Tablet	Deferred for change of brand name
1128.	Carneo Plus Tablet	Deferred for change of brand name
1129.	Ossocal Drops	Deferred for change of brand name
1130.	Delux-D Tablet	Deferred for change of brand name
1131.	Citrovit Drops	Deferred for change of brand name
1132.	Maxiron Drops	Deferred for change of brand name
1133.	Adtive Drops	Deferred for change of brand name
1134.	Azeplex Tablet	Deferred for change of brand name
1135.	Ossocal-D Sachet	Deferred for change of brand name
1136.	Kofect Drops	Deferred for change of brand name
1137.	Primal-Dk Drops	Deferred for change of brand name
Cidex Laboratories, Peshawar		
1138.	Boncal-D Tablet	Deferred for change of brand name
1139.	Fibo-C Sachet	Deferred for change of brand name
1140.	Filbert Sharbat Podina Sharbat	Deferred for the following reasons: <ul style="list-style-type: none"> Form 7, brand name and contents undertakings are unsigned, unstamped. Fee receipt is missing.
1141.	Folit-Q Tablet	Deferred for change of brand name
1142.	Hyomint Suspension	Deferred for change of brand name
1143.	Infa-Ad Tablet	Deferred for the following reasons: <ul style="list-style-type: none"> Form 7, brand name and contents undertakings are unsigned, unstamped. Fee receipt is missing.
1144.	Infa Drop	Deferred for the following reasons: <ul style="list-style-type: none"> Form 7, brand name and contents undertakings are unsigned, unstamped. Fee receipt is missing.
1145.	Migra Fort Tablet	Deferred for change of brand name
1146.	Nutracid Suspension	Deferred for change of brand name
1147.	Triloba Capsule	Deferred for change of brand name
Cure Inn Phytoceuticals Pvt Ltd, Lahore		
1148.	Fevical Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1149.	Parofis Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some

S.No	Brand name	Decision
(1)	(2)	(3)
		product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1150.	Fahcal Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1151.	Iq-Mega Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
Crystolite Pharmaceuticals, Islamabad		
1152.	Xefic 400Mcg Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1153.	Xefic 800Mcg Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1154.	Uribex Tablet	Deferred for change of brand name
1155.	Hairlet Capsule	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1156.	Vitovil Plus Capsule	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.

S.No	Brand name	Decision
(1)	(2)	(3)
1157.	Vitabit Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
Dew Natural Pharma, Lahore		
1158.	Stasmodine Syrup	Deferred for change of brand name
1159.	Dew'S Toot Siah Syrup	Deferred for change of brand name
1160.	Dew-Safi Syrup	Deferred for change of brand name
1161.	Orange-C Syrup	Deferred for change of brand name
1162.	Nurogin Syrup	Deferred for change of brand name
1163.	Grow Fast Baby Tonic Suspension	Deferred for change of brand name
1164.	Dew'S Minti Syrup	Deferred for change of brand name
1165.	Globiton Syrup	Deferred for change of brand name
1166.	Mintdew Syrup	Deferred for change of brand name
1167.	A-Plus Aletris Cordial Syrup	Deferred for change of brand name
1168.	Ivy Kuf Sooth Syrup	Deferred for change of brand name
1169.	Feroton-S Syrup	Deferred for change of brand name
1170.	Kanavit Syrup	Deferred due to Duplication of formulation with Lumi-Vit syrup
1171.	Dew'S Mint Syrup (Sharbat Podina) Syrup	Deferred for change of brand name
1172.	Hycid Antacid Syrup	Deferred for change of brand name
1173.	Ginko-Min Syrup	Deferred for change of brand name
1174.	Honey Dew'S Cough Syrup	Deferred for change of brand name
1175.	Avescon Antacid Syrup	Deferred for change of brand name
1176.	Polybin Syrup	Deferred for change of brand name
1177.	Hemoclean Syrup	Deferred for change of brand name
1178.	Dewcid Syrup	Deferred for change of brand name
1179.	Polykuf Syrup	Deferred for change of brand name
1180.	Lusar Cough Syrup	Deferred for change of brand name
1181.	Luma Cough Syrup	Deferred for change of brand name
1182.	Bonofit-D Suspension	Deferred for change of brand name
1183.	A-Plus Reton Syrup	Deferred for change of brand name
1184.	Honitus Syrup	Deferred for change of brand name
1185.	Stasmodine Drops	Deferred for change of brand name
1186.	Diarrh Syrup	Deferred for change of brand name
1187.	Ginger-Mint Syrup	Deferred for change of brand name
1188.	Orange Plex Syrup	Deferred for change of brand name
Dolphin Laboratories, Lahore		
1189.	Ora-Care Mouth Wash	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1190.	Glow Vera Face Wash	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1191.	Spectrum Sanitizer Gel	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and

S.No	Brand name	Decision
(1)	(2)	(3)
		subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1192.	Aknee Face Wash	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1193.	Gripe Water	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
Eon Pharmacy, Karachi		
1194.	Gasnol Syrup 120Ml Syrup	Form-7 already issued
1195.	Arsal Natural Cough Syrup 120 Ml Syrup	Deferred for change of brand name
1196.	Cough Syrup Junior 120Ml Syrup	Deferred for change of brand name
1197.	Baby Balm Balm	Deferred for change of brand name
1198.	Arsal Balm Balm	Deferred for change of brand name
1199.	Arofen Syrup 120Ml Syrup	Deferred for change of brand name
1200.	Toot Siyah Syrup 120Ml Syrup	Form-7 already issued
1201.	Diarro Syrup (120Ml) Syrup	Deferred for change of brand name
1202.	Gasnol Syrup 120Ml (Sugar Free) Syrup	Deferred for change of brand name
1203.	Analgesic Cream Cream	Deferred for change of brand name
Eson Hi Herb Vision, Islamabad		
1204.	Biocard Plus Tablet	Deferred for change of brand name
1205.	Mg-Crane Sachet	Deferred for change of brand name
1206.	Levitor Tablet	Deferred for change of brand name
1207.	Livitor Syrup	Deferred for change of brand name
1208.	Capillus Capsule	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1209.	Neurit Tablet	Deferred for change of brand name
1210.	Seflex Tablet	Deferred for change of brand name
1211.	Conoff Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1212.	Livin Syrup	Deferred for change of brand name

S.No	Brand name	Decision
(1)	(2)	(3)
1213.	Livin Tablet	Deferred for change of brand name
1214.	Semilex Tablet	Deferred for change of brand name
1215.	Semilex Syrup	Deferred for change of brand name
1216.	Adelin Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1217.	Semibol Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1218.	Vitol Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1219.	Semiter Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1220.	High grow Tablet	Deferred for change of brand name
1221.	High grow Liquid	Deferred for change of brand name
Focus & Rulz Healthcare, Islamabad		
1222.	Satibis Oral Spray Spray	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1223.	Nabimet Capsule Capsule	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.

S.No	Brand name	Decision
(1)	(2)	(3)
1224.	Epidiol Oral Solution Solution	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1225.	Satibis Oral Spray Spray	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1226.	Nabimet Capsule Capsule	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1227.	Epidiol Oral Solution Solution	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
Genetics Healthcare, Lahore		
1228.	Ezegut Capsule	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1229.	Heligut Capsule	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1230.	Biolip Capsule	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are

S.No	Brand name	Decision
(1)	(2)	(3)
		available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1231.	Grab Capsule	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1232.	Sinohale Capsule	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1233.	Reforce Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1234.	Breazy Drops	Deferred for change of brand name
1235.	Deplate 15Mg Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
GreenMan Pharmaceuticals, Rawalpindi		
1236.	Sizepro Tablet	Deferred for change of brand name
1237.	Lekol Capsule	Deferred for change of brand name
1238.	Promass Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether
1239.	Suranjan Arbi Capsule	Deferred for change of brand name
1240.	Barium Meal Sachet	Deferred for change of brand name
1241.	Pepkon-G Capsule	Deferred for change of brand name
1242.	Stoma Care Capsule	Deferred for change of brand name
1243.	Ginkofyt Syrup	Deferred for change of brand name
1244.	Optofyt Tablet	Deferred for change of brand name
Hinucon, Karachi		
1245.	Gevomin Sachet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks.

S.No	Brand name	Decision
(1)	(2)	(3)
		Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether
1246.	Gevomin Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether
1247.	Hinulac Sachet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether
1248.	Hinulac Capsule	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether
1249.	Rimona-Cp 400/10Mg Capsule	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether
1250.	Rimona-Cp 400/20Mg Capsule	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether
1251.	Rimona-Cp 1000/25Mg Sachet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer

S.No	Brand name	Decision
(1)	(2)	(3)
		decision of the instant product application to check its status whether
1252.	Rimona-Cp 1000/50Mg Sachet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether
1253.	Primona 275/75Mg Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether
1254.	Bethin Capsule	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether
1255.	Primona 330/100Mg Capsule	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether
1256.	Primona 275/75Mg Capsule	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether
1257.	Rimona-Cp 2000/150Mg Sachet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether
Hi-Nutrition Pvt Ltd, Lahore		
1258.	C-1000 Mg Effervescent Tablet	Deferred for change of brand name
1259.	C-500 Mg Effervescent Tablet	Deferred for change of brand name
1260.	Zinc Boost Effervescent Tablet	Deferred for change of brand name
1261.	Fe Boost Effervescent Tablet	Deferred for change of brand name


S.No	Brand name	Decision
(1)	(2)	(3)
1262.	Bella Liquid Collagen Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether
1263.	C+Zn Effervescent Tablet	Deferred for change of brand name
Hiranis Pharmaceuticals (Pvt) Limited, Karachi		
1264.	Lokasol Toothpaste	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether
1265.	Lokasol Oral Paste Liquid	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether
Incepta Pharma, Taxila		
1266.	Wrinklex Sachet	Deferred for change of brand name
1267.	Glutaglow Capsules Capsule	Deferred for change of brand name
1268.	Myofert Sachet Sachet	Deferred for change of brand name
1269.	Trufiber Sachet Sachet	Deferred for change of brand name
1270.	Activa Capsules Capsule	Deferred for change of brand name
1271.	Fiberaid Sachet	Deferred for change of brand name
Izfaar Nutraceutical Industries, Lahore		
1272.	Mastito (Vet) Liquid	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether
1273.	Gyno-Far Tablet	Deferred for change of brand name
1274.	Higlob Liquid	Deferred for change of brand name
1275.	Ferofar Liquid	Deferred for change of brand name
Leads Impex Pharma, Lahore		
1276.	M-Fol B Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether
1277.	Giga-Q Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and

S.No	Brand name	Decision
(1)	(2)	(3)
		subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether
Legacy Pharmaceuticals, Peshawar		
1278.	Apricare 500Mg Capsule	Deferred for change of brand name
1279.	Cal Poppy 500Mg Capsule	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether
1280.	Dibcare 10Mg Tablet	Deferred for change of brand name
1281.	Dibcare 25Mg Tablet	Deferred for change of brand name
1282.	Ez Rest Capsule	Deferred for change of brand name
1283.	Happy Mood 500Mg Capsule	Deferred for change of brand name
1284.	Lesschol 375Mg Tablet	Deferred for change of brand name
1285.	Lesschol 500Mg Tablet	Deferred for change of brand name
1286.	Livosmin 375Mg Capsule	Deferred for change of brand name
1287.	Livosmin Plus Capsule	Deferred for change of brand name
1288.	Magtim 1000Mg Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether
1289.	Saw Pal 800Mg Capsule	Deferred for change of brand name
M.R.G Laboratories, Karachi		
1290.	Hecho Sachet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether
1291.	Celimixt Sachet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether
1292.	Culturela Sachet	Deferred for change of brand name
1293.	Ener-C Sachet	Deferred for change of brand name
Mediformers Neutraceutical, Lahore		
1294.	Neutroon Capsule	Deferred for change of brand name
Medinoon Research Laboratories, Lahore		
1295.	Naslus Suspension	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and

S.No	Brand name	Decision
(1)	(2)	(3)
		subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether
1296.	Dravit-D Oral Drops	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether
1297.	Nthiron Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether
Merit Pvt. Ltd., Lahore		
1298.	Marit Ors Sachet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether
MRG Laboratories, Karachi		
1299.	Howatic Sachet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether
MTI Medical, Lahore		
1300.	Estosan Suspension	Deferred for change of brand name
1301.	Efron Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether
1302.	Lifolac Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names

S.No	Brand name	Decision
(1)	(2)	(3)
		are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether
1303.	Zocobin Syrup	Deferred for change of brand name
1304.	Cistimax Syrup	Deferred for change of brand name
1305.	Sampa Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether
1306.	Complivit Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether
Nascon Pharmaceutical, Peshawar		
1307.	Folic Acid Tablet	Deferred for change of brand name
1308.	Feuromin Tablet	Deferred for change of brand name
1309.	Panthomine-M	Deferred for change of brand name
1310.	Irocon Tablet	Deferred for change of brand name
1311.	Cal-D Fort Tablet	Deferred for change of brand name
1312.	Camzol-D Tablet	Deferred for change of brand name
1313.	Calcon-D Tablet	Deferred for change of brand name
1314.	Endomax Tablet	Deferred for change of brand name
1315.	Cidlock Sachet	Deferred for change of brand name
1316.	Uroflux Tablet	Deferred for change of brand name
1317.	Trihad Capsule	Deferred for change of brand name
1318.	Sleepwel Tablet	Deferred for change of brand name
1319.	Sleepwel Drops	Deferred for change of brand name
1320.	Ido Folic Acid Tablet	Deferred for change of brand name
1321.	Aormin-D Drops	Deferred for change of brand name
1322.	Lemo Cid Syrup	Deferred for change of brand name
1323.	Ginsol Syrup	Deferred for change of brand name
1324.	Podina Adrak Plus Calvange Syrup	Deferred for change of brand name
1325.	Megzora-D Drops	Deferred for change of brand name
Nigehban, Karachi		
1326.	Nourish & Flourish Whitening Face Wash	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether
1327.	Foot Repair Cream	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer

S.No	Brand name	Decision
(1)	(2)	(3)
		decision of the instant product application to check its status whether
1328.	Nutra Shampoo	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether
1329.	Nutra Conditioner	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether
1330.	Nourish & Flourish Whitening Whitening Cream	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether
1331.	Revitalise Moisturizing Cream	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether
1332.	Nourish & Flourish Whitening Acne Face Wash	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether
Nutrabiobiotics Nutritional Life Sciences, Peshawar		
1333.	Pre-Vomit Capsule	Deferred for change of brand name
1334.	Foliget Tablet	Deferred for change of brand name
1335.	E-Vita Tablet	Deferred for change of brand name
1336.	Genmax Capsule	Deferred for change of brand name
1337.	Agcal-D Tablet	Deferred for change of brand name
1338.	Ginsavin Tablet	Deferred for change of brand name
1339.	Getcall-D Sachet	Deferred for change of brand name
1340.	Flexi D Tablet	Deferred for change of brand name
1341.	Subtize Syrup	<ul style="list-style-type: none"> Deferred for change of brand name. Strength of extract of each ingredient individually is required.
1342.	Due Fee	Deferred for change of brand name
Nutrifactor Laboratories (Pvt) Ltd, Faisalabad		
1343.	Apifocus Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks.

S.No	Brand name	Decision
(1)	(2)	(3)
		Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether
1344.	Qfend Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether
1345.	Nurozon Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether
Oasis Pharma, Lahore		
1346.	VibroX Tablet	Deferred for change of brand name
1347.	Osigain Softgel Capsule	Deferred for change of brand name
1348.	Ovi-Safe Sachet	Deferred for change of brand name
1349.	Maxy Barry Sachet	Deferred for change of brand name
1350.	Protec-1 Syrup	Deferred for change of brand name
1351.	Methlox Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
Opal Laboratories, Karachi		
1352.	Cberry C Effervescent Sachet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1353.	Cberry C Plus Effervescent Sachet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1354.	Bc-Lyse Plus Syrup	Deferred for the following reasons: <ul style="list-style-type: none"> Brand name to be change. 

S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> Formulation contains herbs with vitamins while the firm possess only nutraceutical facility
Paramount Healthcare, Islamabad		
1355.	Maxofol Plus Tablet	Deferred for change of brand name
1356.	Irocrib 120Ml Syrup	Deferred for change of brand name
1357.	Irocrib 65Mg Tablet	Deferred for change of brand name
1358.	Myocure-D Sachet	Deferred for change of brand name
1359.	Myocure Tablet	Deferred for change of brand name
Parina Pharma Pvt Ltd, Karachi		
1360.	Iv-Zone Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1361.	Otizer Syrup	Deferred for change of brand name
1362.	Vitazone Syrup	Deferred for change of brand name
1363.	Ozocid Syrup	Deferred for change of brand name
Phytotia Laboratory, Peshawar		
1364.	Folrex-F Tablet	Deferred for change of brand name
1365.	Folrex-L Tablet	Deferred for change of brand name
1366.	Iroomax Tablet	Deferred for change of brand name
Regimen Nutraceuticals, Lahore		
1367.	Eyzi Capsule	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
RG Pharmaceutica (Pvt.) Ltd., Lahore		
1368.	Refrid Sachet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1369.	Maxocid Sachet	Deferred for change of brand name
1370.	Neend Syrup	Deferred for change of brand name
1371.	Sistove Sachet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1372.	D-Congesta Drops	Deferred for change of brand name
1373.	Flumca Sachet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some

S.No	Brand name	Decision
(1)	(2)	(3)
		product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1374.	Easup Drops	Deferred for change of brand name
1375.	Glucoliq Sachet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1376.	Minfant Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1377.	Osteosam Tablet	Deferred for change of brand name
1378.	Grobaby Drops	Deferred for change of brand name
1379.	Interact Sachet	Deferred for change of brand name
1380.	Colibid Drops	Deferred for change of brand name
1381.	Menorag Tablet	Deferred for change of brand name
1382.	Proantho Sachet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1383.	Neend Drops	Deferred for change of brand name
1384.	Stooler Drops	Deferred for change of brand name
1385.	Locyst Tablet	Deferred for change of brand name
1386.	Maxperm Sachet	Deferred for change of brand name
1387.	Optimune Syrup	Deferred for change of brand name
1388.	Diafol Tablet	Deferred for change of brand name
1389.	Acd Plus Drops	Deferred for change of brand name
1390.	Myfol Syrup	Deferred for change of brand name
1391.	Myfol Drops	Deferred for change of brand name
1392.	Myfol Tablet	Deferred for change of brand name
Sancura Pharma, Karachi		
1393.	Ovit-M Soft Gel Capsules	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1394.	Suprafit Tablet	Deferred for change of brand name
1395.	Epo-Soft Softgel Capsule	Deferred for change of brand name
1396.	Calci Lock-D Softgel Capsules	Deferred for change of brand name
1397.	Lm-Fol Tablet	Deferred for change of brand name

S.No	Brand name	Decision
(1)	(2)	(3)
1398.	Orsup-D Tablets	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1399.	Precon Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1400.	Ultra-D Softgel Capsules	Deferred for change of brand name
1401.	Cardimox Softgel Capsule	Deferred for change of brand name
1402.	Redmax Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1403.	Cransure Sachet	Deferred for change of brand name
1404.	Ivy Cof Syrup	Deferred for change of brand name
1405.	Cal Soft Gel Capsule	Deferred for change of brand name
1406.	Folimax Softgel Capsules	Deferred for change of brand name
1407.	Ris Cal Syrup	Deferred for change of brand name
Saviour Pharma, Lahore		
1408.	Ss-Vit Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
Scotmann Pharmaceutical, Islamabad		
1409.	Dayvit Tablet	Deferred for change of brand name
1410.	Eziman Tablet	Deferred for change of brand name
1411.	Becom Capsule	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1412.	Unpause Tablet	Deferred for change of brand name
SHMZ Labs & Pharmaceuticals, Lahore		
1413.	Calcinix Syrup	Deferred for change of brand name
1414.	Cal-Lac Syrup	Deferred for change of brand name
1415.	Calsun Tablet	Deferred for change of brand name
1416.	Coral-Vit Tablet	Deferred for change of brand name

S.No	Brand name	Decision
(1)	(2)	(3)
1417.	Iroon-F Syrup	Deferred for change of brand name
1418.	Macovit-Advance Tablet	Deferred for change of brand name
1419.	Mensofort Syrup	Deferred for change of brand name
1420.	Sharbat Podina Syrup	Deferred for change of brand name
1421.	Unicorn Syrup	Deferred for change of brand name
Sigma Life Pharmaceuticals, Rawalpindi		
1422.	Cran Life Syrup	Deferred for change of brand name
1423.	Fitliv Syrup	Deferred for change of brand name
1424.	Osofit Syrup	Deferred for change of brand name
1425.	Liver Dtx Syrup	Deferred for change of brand name
Sois Life Sciences, Karachi		
1426.	Calgi Forte Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
Steg laboratories, Sheikhpura		
1427.	Retipal-A Softgel	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1428.	Elevit-E400 Softgel	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1429.	Elevit-E200 Softgel	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1430.	Cheervit Softgel	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1431.	Elevit-E600 Softgel	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some

S.No	Brand name	Decision
(1)	(2)	(3)
		product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
Tehseen Industries Lahore		
1432.	Cola Gin Tablet	Deferred for change of brand name
1433.	Cola Gin Sachet	Deferred for change of brand name
1434.	Bone Plus Tablet	Deferred for change of brand name
1435.	Bone Plus Syrup	Deferred for change of brand name
1436.	Vitagim Syrup	Deferred for change of brand name
1437.	Vitagim Tablet	Deferred for change of brand name
1438.	Leadofor Syrup	Deferred for change of brand name
1439.	Folic Plus	Deferred for change of brand name
Verbana International, Islamabad		
1440.	Blue Min P Powder	Deferred for change of brand name
1441.	T-Tox	Deferred for change of brand name
1442.	Dcp-Vet Powder	Deferred for change of brand name
1443.	Ab Entol Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1444.	T-Plcenta Off Sachet	Deferred for change of brand name
1445.	Immune Plus Liquid	Deferred for change of brand name
1446.	Bull Max Powder	Deferred for change of brand name
1447.	Respo-Vet Liquid	Deferred for change of brand name
1448.	Appetonic Liquid	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1449.	Masti Cure Liquid	Deferred for change of brand name
1450.	Dairy Gold Powder	Deferred for change of brand name
Vida Laboratories, Karachi		
1451.	Fair Plus Cream	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1452.	Fair Plus Cream	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.

S.No	Brand name	Decision
(1)	(2)	(3)
1453.	Osia (Cholecalciferol) 100000Iu Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1454.	Ornafen Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
Viegen Pharma, Lahore		
1455.	Xtramen Tablet	Deferred for change of brand name
1456.	Ossetrol Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1457.	Peptol Suspension	Deferred for change of brand name
1458.	Tulac Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1459.	Livsire Syrup	Deferred for change of brand name
1460.	Mucare Syrup	Deferred for change of brand name
1461.	Ultr Co-Q10 Tablet	Deferred for change of brand name
1462.	Urined Sachet	Deferred for change of brand name
1463.	Vyfat Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
Vital Mark Laboratories Pvt Ltd, Fasialabad		
1464.	Vita Dressing Spray	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer

S.No	Brand name	Decision
(1)	(2)	(3)
		decision of the instant product application to check its status whether it has been disposed of or otherwise.
1465.	Vita Trust Extra Liquid	Deferred for change of brand name
1466.	Vitox M Powder	Deferred for change of brand name
1467.	Vitagest Powder	Deferred for change of brand name
Wilshire Laboratories Pvt Ltd, Lahore		
1468.	Calcimax Tablet	Deferred for change of brand name
Wilson's Healthcare, Islamabad		
1469.	Serowil Tablet 60,000Iu Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
1470.	Serowil Tablet 60,000Iu Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
Xecutive Pharma, Lahore		
1471.	Ph Pro Tablet	Deferred for change of brand name
1472.	Multipro M Tablet	Deferred for change of brand name
1473.	Ad-Folvitic Tablet	Deferred for change of brand name
1474.	Lowcid Syrup	Deferred for change of brand name
1475.	A+ Farfly Syrup	Deferred for change of brand name
1476.	Spasmo Syrup	Deferred for change of brand name
1477.	Respivil Syrup	Deferred for change of brand name
1478.	Onefolin Tablet	Deferred for change of brand name
1479.	Apiget Syrup	Deferred for change of brand name
1480.	Perinef Tablet	Deferred for change of brand name
1481.	Osserise Tablet	Deferred for change of brand name
1482.	Diazik Tablet	Deferred for change of brand name
1483.	Citiflow Tablet	Deferred for change of brand name
1484.	Ardin Syrup	Deferred for change of brand name
Zahi Nutraceutical Laboratories, Peshawar		
1485.	Deone-3 Capsule	Deferred for change of brand name
1486.	Naom Capsule	Deferred for change of brand name
1487.	Ked-3 Drops	Deferred for change of brand name
1488.	Cren Mxx Maya Syrup	Deferred for change of brand name
1489.	Amlite Capsule	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
M/s Dew Max Pharmaceuticals Pvt Ltd, Plot No 6, Street S-6, National Industrial Zone, RCCI, Rawat, holding Drug Manufacturing License No.000889 (Contract Givers), has submitted the application vide letter No. Nil, dated 11-02-2022, for provisional product enlistment on basis of contract manufacturing from M/s Damac Healthcare, located at Plot No. 5, Street No. N-1 E1, RCCI Industrial Estate, Rawat, (Enlistment No. 01233) (Contract Acceptor)		
1490.	Dew-Max's Dew-Flex	Deferred for clarification regarding rationality of formulation along with role of ingredients
M/s Serena Laboratories, 16-17/C, Punjab Small Industrial Estate, Ferozpur Road, Kasur, holding Provisional Enlistment No.01094, has submitted the application, vide letter No. Nil, submitted on 24-08-2022, for contract		



S.No	Brand name	Decision
(1)	(2)	(3)
manufacturing from M/s Zodiac Pharma, located at 7-Km Off Raiwind – Manga Road, Near Haveli Bangroo Wali, Mouza Mull, Lahore (E.No.01110);		
1491.	Lactil Drop	Deferred for confirmation of Lactase enzyme as a health product
M/s My Health Pharma (Pvt) Ltd., located at the address Plot No.589, Sundar Industrial Estate, Raiwind Road, Lahore, holding Provisional Enlistment No.00620, has submitted the application, vide letter No. Nil, submitted on 24-08-2022, for contract manufacturing from M/s Zodiac Pharma, located at 7-Km Off Raiwind – Manga Road, Near Haveli Bangroo Wali, Mouza Mull, Lahore (E.No.01110).		
1492.	Lacto Lic Drop	Deferred for confirmation of Lactase enzyme as a health product
M/s Tibb-e-Mashriq Dawakhana, located at Chak No.7/11-L, Ada Dad Fatiana, Tehsil Chichawatni, District Sahiwal, holding Provisional Enlistment No.01097, has submitted the application, vide letter No. Nil, submitted on 24-08-2022, for contract manufacturing from M/s Zodiac Pharma, located at 7-Km Off Raiwind – Manga Road, Near Haveli Bangroo Wali, Mouza Mull, Lahore (E.No.01110).		
1493.	Getlac Drop	Deferred for confirmation of Lactase enzyme as a health product
M/s New Syed Pharma, located at the address 7-km Sheikhpura Road, Muridke, holding Provisional Enlistment No.00415, has submitted the application, vide letter No. Nil, submitted on 24-08-2022, for contract manufacturing from M/s Zodiac Pharma, located at 7-Km Off Raiwind – Manga Road, Near Haveli Bangroo Wali, Mouza Mull, Lahore (E.No.01110).		
1494.	Hytase Drop	Deferred for confirmation of Lactase enzyme as a health product.
M/s Tibb-e-Mashriq Dawakhana, located at Chak No.7/11-L, Ada Dad Fatiana, Tehsil Chichawatni, District Sahiwal, (Enlistment No. 01097), has submitted the application, vide letter No. Nil, received on 24-08-2022, for contract manufacturing from M/s Xecutive Pharma, located at Plot No. 47-A, Punjab Small Industrial Estate – II, Sundar, Lahore (E.No.01272)		
1495.	Mentizo Capsule	Deferred for clarification regarding rationality of formulation
M/s Zodiac Pharma, located at 7-Km Off Raiwind – Manga Road, Near Haveli Bangroo Wali, Mouza Mull, Lahore, (Enlistment No. 01110), has submitted the application, vide letter No. Nil, received on 24-08-2022, for contract manufacturing from M/s Xecutive Pharma, located at Plot No. 47-A, Punjab Small Industrial Estate – II, Sundar, Lahore (E.No.01272).		
1496.	IB-Mint Capsule	Deferred for clarification regarding rationality of formulation
M/s Macter International Limited, F-216, SITE, Karachi, holding Drug Manufacturing License No.000111, has submitted the application vide letter No. Nil, submitted on 10-08-2022, for permission of contract manufacturing from M/s Trends Pharmaceuticals (Nutraceuticals & Cam Division), located at Plot 546/ 547, Sundar Industrial Estate, Lahore.		
1497.	IB-Mac Syrup	Deferred for provision of exact species of Angelica along with scientific evidences that the said ingredient does not contain phototoxic furanocumarins.
M/s Helix Pharma (Pvt.) Ltd., located at A58/B, S.I.T.E, Manghopir Road, Karachi, holding Provisional Enlistment No. 00226, has submitted the application, vide letter No. Nil, submitted on 22-08-2022, for contract manufacturing from M/s Neu Mex Healthcare Laboratories., located at the address Plot No.162-C, Sector 24, Korangi Industrial Area, Karachi, (Enlistment No. 00728).		
1498.	Nayspa Drops	Deferred for confirmation of Lactase enzyme as a health product
M/s Palpex Pharmaceuticals Pvt Ltd, Plot No Fd-46-A8, Street I, Sector 38, Korangi Creek Industrial Park, Karachi, holding Drug Manufacturing License No. 000858, has submitted the application, vide letter No. Nil, submitted on 16-08-2022, for contract manufacturing from M/s Neu Mex Healthcare Laboratories., located at the address Plot No.162-C, Sector 24, Korangi Industrial Area, Karachi, (Enlistment No. 00728).		
1499.	Munolact Drops	Deferred for confirmation of Lactase enzyme as a health product


(Ayyaz Ahmad)

Secretary, Enlistment Evaluation Committee

ANNEXURE

The firm is directed to submit soft data in both MS Excel & MS Word on following formats in **USB ONLY**.

MS Excel Format

Sr. No.	Company name	Product Name	Dosage Form	Composition	Common name	Recommended use	Pack Size	Date of R&I submission
1.	(Company name, City) Without address	XYZ	Tablet	Each tablet contains: Abc (USP)...50mg	XXX	XXX	10's 20's	DD.MM.Y YYY
2.								

MS Word Format

Sr. No.	Company name	Product Name and composition	Common name	Recommended use	Pack Size
1.	(Company name, City) Without address	XYZ Tablet Each tablet contains: Abc (USP)....50mg	XXX	XXX	10's 20's
2.					